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GSK3BETA-MEDIATED EZH2 PHOSPHORYLATION
SUPPRESSES METHYLATION OF H3K27 AND EZH2’S
ONCOGENIC FUNCTIONS

How-Wen Ko, M.D.
Advisory Professor: Mien-Chie Hung, Ph. D.

During the process of tumorigenesis, inactivation of tumor suppressors is a critical
step. Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase and the
enzymatic core subunit of polycomb repressive complex 2 (PRC2), promotes cell
growth and migration through catalyzing trimethylation of histone H3 at Lys 27
(H3K27me3) and plays an important role in tumorigenesis. Its expression can be
controlled by phosphorylation. However, the regulation of EZH2 activity by tumor
suppressor kinase is not well understood. Glycogen synthase kinase 3 beta
(GSK3), a multifunctional serine/threonine kinase, is involved in many cellular
processes. GSK3 also participates in neoplastic transformation, tumor
development and regulate cancer cell metastasis. Inactivation of GSK3
contributes to tumor development in certain types of cancers, such as breast
cancer. In this study, we found that GSK3 negatively regulates H3K27
trimethylation. We also validated that GSK3 physically interacts with EZH2 and
their interaction mainly exists in the cytosol. GSK3 phosphorylates EZH2 at
Ser363 and Thr367 in vitro, and activating GSK3 upregulates Thr367
phosphorylation in vivo. Cells expressing mutant EZH2 to block phosphorylation by
v

GSK3 have higher H3K27 trimethylation and enhanced ability of cell migration and
anchorage-independent growth. Inactivation of GSK3 as measured by its
phosphorylation at Ser9 is positively correlated with higher level of H3K27
trimethylation in breast cancer patients. Our study indicates that GSK3 has a
critical role in regulating EZH2-mediated oncogenesis.
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Chapter 1
Introduction

1

1-1 Epigenetic regulations and cancer
Epigenetic regulation is an important mechanism in mediating gene
expressions through modifying chromatin structure without changing DNA
sequence. It is critical in DNA-based processes, such as transcription, DNA
replication and repair, and essential for cell fate specification and normal tissue
development. Chromatin consists of DNA and histone proteins, providing the
platform for package of whole genome. The basic unit of chromatin is the
nucleosome, which contains 147 base pairs of DNA wrapped around a histone
octomer. Epigenetic mechanisms include DNA methylation, histone modifications,
nucleosome remodeling and incorporation of histone variants, and non-coding
RNAs (Henikoff and Ahmad 2005, Kouzarides 2007, Suzuki and Bird 2008, Jiang
and Pugh 2009, Esteller 2011). All these mechanisms can work together to regulate
gene expressions by altering compactness and accessibility of chromatin. The
interaction between these modifications demonstrates an “epigenetic landscape”,
and determines and maintains tissue-specific gene expression patterns.
Aberrations in the processes alter normal gene expressions, cause activation or
inactivation of regular signaling pathway, and lead to disease states like cancer
(Sharma, Kelly et al. 2010).
Cancer is a disease arising from the accumulation of genetic abnormalities.
Evidence has revealed that epigenetic abnormalities contribute to cancer initiation
and progression. Epigenetic deregulations can cause silencing of tumor suppressor
genes or activation of oncogenes, resulting in uncontrolled cell growth. These
deregulations result from alterations in the patterns of DNA methylation and histone
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modifications as well as abnormal expressions or mutations of chromatin-modifying
enzymes. These genetic and epigenetic abnormalities can interact with each other
to promote tumorigenesis. Unlike genetic mutations in cancers, epigenetic
alterations are potentially reversible. Because of this character, therapies against
epigenetic aberrations have been developed for specific cancer management and
some of them have been approved (Dawson and Kouzarides 2012).

1-2 Polycomb group proteins, PRC2 complex and EZH2
Polycomb group (PcG) proteins control gene silencing through histone
modifications and are essential epigenetic regulators in cell differentiation and
tissue development. Their deregulations have been implicated in cancer
development. Polycomb group proteins were originally discovered in Drosophila
melanogaster as transcriptional repressors of HOX genes, a gene family controlling
development of anterior-posterior body segmentation. They have later been
recognized as key mediators in cell fate determination and play an essential role in
epigenetic regulation (Sauvageau and Sauvageau 2010). In vertebrates, they have
similar

effects

on

maintenance

of

homeotic

gene

expression

patterns

(Schuettengruber, Chourrout et al. 2007). Polycomb group proteins are well
conserved between Drosophila and mammals. In mammals, two major multiprotein
complexes have been identified, polycomb repressive complex 1 and 2 (PRC1 and
PRC2). The compositions of these two complexes may be variable among
organisms and cell context-dependent, but each complex contains common core
components (Sauvageau and Sauvageau 2010). Core components of PRC1
complex include ring finger protein RING1A/B, chromobox homolog (CBX), B
3

lymphoma Mo-MLV insertion region 1 (BMI1), polyhomeotic homolog (PH), and
SCML subunits. The PRC1 complex monoubiquitylates histone H2A at Lys 119
(H2AK119ub1) through its catalytic subunit, ubiquitin E3 ligase RING1 protein, to
generate a repressive mark in chromatin structure. Core components of PRC2
complex contain enhancer of zeste homolog 2 (EZH2), embryonic ectoderm
development (EED), suppressor of zeste 12 (SUZ12) and retinoblastoma
suppressor associated protein 46/48 (RbAp46/48). The PRC2 complex catalyzes
trimethylation of histone H3 at Lys 27 (H3K27me3) to epigenetically silencing
specific

gene

expressions

via

enzymatic

core

subunit,

lysine

histone

methyltransferase EZH2. PRC1 and PRC2 work together to repress gene
transcription (Margueron and Reinberg 2011). Once the PRC2 complex is recruited
to chromatin, EZH2 catalyzes histone H3 to generate H3K27me3 mark.
Subsequently, the PRC1 complex is recruited to interact with H3K27me3 through
its chromodomain-containing subunit, CBX, thereby catalyzing H2AK119ub1 to
impede RNA polymerase II-dependent transcriptional elongation, thereafter
repressing gene transcription. However, both complexes have independent
functions in transcription repression (Eskeland, Leeb et al. 2010). Another groups
of proteins, Trithorax group (TrxG) proteins, work as the functional counter parts of
polycomb group proteins. They were also initially identified in Drosophila and are
known to be crucial in cell differentiation and tissue development. Trithorax group
proteins modify chromatin structure through catalyzing trimethylation of histone H3
at Lys 4 (H3K4me3) and serve as transcriptional activators of gene expression
(Schuettengruber, Martinez et al. 2011). The H3K27me3 and H3K4me3 act as

4

repressive and active marks in epigenetic regulation. Active histone marks barely
co-exist with H3K27me3 on the same histone tail (Schmitges, Prusty et al. 2011,
Voigt, LeRoy et al. 2012). In certain context like embryonic stem (ES) cells, these
two histone marks occur concurrently on the same nucleosome as “bivalent
domains” to regulate the expressions of developmentally important genes
(Bernstein, Mikkelsen et al. 2006, Margueron and Reinberg 2011).
In many types of solid cancers, increased expressions of PRC2 components
have been reported (Varambally, Dhanasekaran et al. 2002, Kleer, Cao et al. 2003,
Bachmann, Halvorsen et al. 2006, Li, Cai et al. 2012, Yu, Simons et al. 2012, Sato,
Kaneda et al. 2013, Xia, Jin et al. 2015). Furthermore, regions within chromatin
structure that are hypermethylated in cancers are often found to be pre-marked by
H3K27me3 in embryonic stem cells (Ohm, McGarvey et al. 2007, Schlesinger,
Straussman et al. 2007). This evidence has linked the developmental regulation to
tumorigenesis and suggests an important role of PRC2 complex in cancer.
Human EZH2 gene was mapped to chromosome 7q35, which encodes protein
containing 746 amino acids (Cardoso, Mignon et al. 2000). The functional domains
of EZH2 include: WD-40 binding domain (WDB), domains I & II, two SWI3, ADA2,
N-CoR and TFIIIB (SANT) domains, cysteine-rich CXC domain and evolutionarily
conserved SET domain. WD-40 binding domain is EED binding region, thus also
called EED interacting domain (EID). Domain II is area for interaction with SUZ12.
SANT domains are responsible for interaction with histone peptides. SET domain,
located at C-terminal region of EZH2, is required for histone methyltransferase
activity of EZH2/PRC2 complex (Margueron and Reinberg 2011, Li 2014, Tan, Yan
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et al. 2014). Another enhancer of zesta homolog (EZH) is EZH1. EZH1 mainly
exists in differentiated cells, whereas EZH2 is predominately expressed in
proliferative tissues. PRC2 complex containing either EZH2 or EZH1 possesses
histone methyltransferase activity but the complex of PRC2-EZH1 has markedly
reduced enzymatic activity and different chromatin binding properties (Margueron,
Li et al. 2008).

1-3 Enzymatic activity and functions of EZH2
The best characterized enzymatic activity of EZH2/PRC2 complex is the
trimethylation of H3K27 (Cao, Wang et al. 2002, Kuzmichev, Nishioka et al. 2002).
In mammals, PRC2 complex is probably the only enzyme known to catalyze the
methylation of H3K27 and it post-translationally modifies this residue in a
successive manner from the monomethylation to the trimethylation (H3K27me1,
H3K27me2, H3K27me3) (Kadoch, Copeland et al. 2016). Steady state kinetic
studies of PRC2 containing EZH2 demonstrated that PRC2 complex preferentially
catalyze the first methylation reaction (H3K27me1 as product) rather than the
second and third reactions (H3K27me2 and H3K27me3 are products, respectively)
(Sneeringer, Scott et al. 2010). The enzymatic activity of lysine methyltransferases
depends on a catalytic domain, SET domain that consists of an Sadenosylmethionine (SAM)-binding site and a methyl acceptor lysine-binding site
(Copeland, Solomon et al. 2009). These protein enzymes catalyzes methylation by
the addition of methyl groups to their substrates at specific amino acids. EZH2 is
the catalytic core subunit of PRC2 complex, which contains a SET domain.
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However, EZH2 alone lacks of enzymatic activity and it requires a minimum of two
additional PRC2 subunits, EED and SUZ12, for its robust histone lysine
methyltransferase activity (Cao and Zhang 2004, Pasini, Bracken et al. 2004,
Montgomery, Yee et al. 2005). EED is a WD-repeat protein, with a doughnut-like
structure that offers a scaffold for association with its interacting proteins, such as
EZH2 and H3K27me3. The region of EZH2 responsible for EED binding is Nterminal fragment (around residues 35-70) (Han, Xing et al. 2007, Tan, Yan et al.
2014). In addition, EED can directly bind H3K27me3, which recruits PRC2 complex
to regions within chromatin for further repression (Hansen, Bracken et al. 2008,
Margueron, Justin et al. 2009). It has also been reported that binding of EED to
H3K27me3 can stimulate EZH2 enzymatic activity (Margueron, Justin et al. 2009).
SUZ12 is also necessary for the histone methyltransferase activity of PRC2
complex, but how it contributes to the enzymatic action remains elusive. SUZ12 has
been shown to be able to stabilize the PRC2 complex (Cao and Zhang 2004, Pasini,
Bracken et al. 2004, Jiao and Liu 2015). A study has demonstrated that dense
chromatin can activate PRC2 activity to regulate H3K27me3, which is in part
mediated by SUZ12 (Yuan, Wu et al. 2012). SUZ12 is a zinc-finger protein, which
contains a conserved VRN2-EMF2-FIS2-SUZ12 (VEFS) domain at its C-terminal
region. Deletion of this domain disrupts SUZ12-EZH2 interaction and leads to
dissociation of PRC2 complex (Yamamoto, Sonoda et al. 2004). Mutations in this
domain do not affect the assembly of PRC2 complex but reduce its enzymatic
activity (Rai, Vargas et al. 2013). Furthermore, it has been shown that C-terminal
region of SUZ12 harboring VEFS domain is the minimal requirement for the histone
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methyltransferase activity of PRC2 complex (Schmitges, Prusty et al. 2011). Other
PRC2 components, such as RbAp46/48, AEBP2, and JARID2, also contribute to
PRC2’s enzymatic activity (Margueron and Reinberg 2011). However, they function
as accessory rather than essential factors.
Although the composition of PRC2 complex may vary, all PRC2 either
containing EZH1 or EZH2 primarily catalyzes methylation of H3K27. The reaction
of methylation is stepwise as aforementioned. In mammalian cells, methylated
H3K27 is abundant and all three forms exist. Mass spectrometry (Peters, Kubicek
et al. 2003) and proteomic analyses (Ferrari, Scelfo et al. 2014) revealed that in
mouse embryonic stem cells most H3K27 is methylated (around 80%) and the
majority of methylated H3K27 is dimethylation form (50~70%). Monomethylation
and trimethylation of H3K27 occur in about 5% and 10%, respectively. H3K27me3
is a stable mark and its enrichment is related to gene silencing. In contrast,
H3K27me2 seems to be less important in gene repression, yet it may be a critical
intermediate product. It has been proposed that H3K27me2 is a substrate for
subsequent formation of H3K27me3 mark via monomethylation and it may also
facilitate the action of PRC2 by prevention of H3K27 acetylation (Margueron and
Reinberg 2011). Both H3K27me3 and H3K27me2 are associated with gene
silencing, while the enrichment of H3K27me1 throughout the gene bodies has been
found to be related to actively transcribed genes (Ferrari, Scelfo et al. 2014).
Despite H3K27me1 is produced by PRC2 complex through catalyzing
monomethylation of H3K27, it is still detected in cells expressing non-functional
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PRC2 (Schoeftner, Sengupta et al. 2006). How is H3K27me1 generated in cells is
not fully understood.
Genome-wide screening for the distribution of PRC2 complex and H3K27me3
have been explored in human and mouse embryonic stem cells, in which
H3K27me3 has been found to be enriched in the promoter regions where are also
occupied by PRC2 complex (Pan, Tian et al. 2007, Zhao, Han et al. 2007). Several
target genes, such as HOX genes and other developmental regulators, have been
identified (Boyer, Plath et al. 2006, Lee, Jenner et al. 2006). On the other hand, the
interaction of PRC2 complex with other factors facilitates PRC2 recruitment to its
specific loci. Many of transcription factors, including Ying Yang 1 (YY1), interact
with EZH2 to promote recruitment of PRC2 complex to target site for gene silencing
(Palacios, Mozzetta et al. 2010). Non-coding RNAs (ncRNA), such as HOX
transcript antisense RNA (HOTAIR), also interact with PRC2 complex and play an
important in the recruitment of PRC2 complex the specific loci (Tsai, Manor et al.
2010).
EZH2 also cooperates with other epigenetic regulators to modulate gene
expression. It has been shown that EZH2 physically interacts with and recruits DNA
methyltransferases, DNMT1, DNMT3A and DNMT3B, to methylate target genes
and to establish a more deeply silenced chromatin state (Vire, Brenner et al. 2006).
In addition, histone deacetylatses (HDAC) also contribute to the methylation of
PRC2. Lys 27 of histone H3 can be acetylated. If H3K27 is acetylated, a HDAC is
required before the action of PRC2 complex. HDAC modifies the local histone code
of genes prepared for silencing through deacetylation of H3K27, thereby making
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H3K27 available for methylation by PRC2 (van der Vlag and Otte 1999, Tie,
Furuyama et al. 2001). The interaction between EZH2 and DNMT, or EZH2 and
HDAC, has also been found to contribute to tumor development (Tong, Cai et al.
2012, Ning, Shi et al. 2015).
Recently, EZH2 has been shown to methylate substrates other than histone.
EZH2 interacts with and methylates a cardiac transcription factor, GATA4 at Lys
299. PRC2-mediated methylation of GATA4 disrupts GATA4’s interaction with
p300, which suppresses GATA4’s transcription activity (He, Shen et al. 2012).
EZH2 also monomethylates retinoic acid-related orphan nuclear receptor α (RORα)
at Lys 38 (Lee, Lee et al. 2012). Monomethylated RORα is recognized and
ubiquitinated by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex. EZH2mediated methylation leads to RORα’s degradation and represses its target gene
expression. These studies provide evidence showing that PRC2 or EZH2 can
repress gene transcription through mediating non-histone targets. Moreover, it has
been demonstrated that EZH2 transcriptionally activates androgen receptor (AR)’s
target genes through interaction with and methylation of AR or AR-associated
proteins (Xu, Wu et al. 2012). EZH2 also binds to and methylates signal transducer
and activator of transcription 3 (STAT3) at Lys 180, which increases STAT3 activity
and leads to transcription activation (Kim, Kim et al. 2013). These evidence
indicates that EZH2 can activate gene expression through its methyltransferase
activity in a polycomb-independent manner.
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1-4 Regulation of EZH2 expression and activity
EZH2 level is low in differentiated cells (Varambally, Dhanasekaran et al.
2002, Kleer, Cao et al. 2003) but is relatively high in embryonic stem cells or
undifferentiated progenitors of adult tissues (Su, Basavaraj et al. 2003), which
suggests that EZH2 is essential in cell differentiation. In cancer, EZH2 is frequently
overexpressed and has been found to be implicated in cancer cell growth and
survival (Yamaguchi and Hung 2014). Thus, the regulators of EZH2 expression are
critical for these cellular processes and understanding the underlying molecular
mechanisms is important. Several transcription factors or signaling pathways
regulate the expression of EZH2. pRB-E2F signaling has been demonstrated to be
involved in EZH2 overexpression (Bracken, Pasini et al. 2003). EZH2 is
downstream of this pathway and E2F positively controls EZH2 expression.
Phosphorylation of retinoblastoma (RB) dissociates E2F from the pRB-E2F
complex. The binding of dissociated E2F to the EZH2 promoter up-regulates EZH2
transcription. Deregulation of this pathway or E2F overexpression is correlated with
higher expression of EZH2 in breast cancer and small cell lung cancer (Bracken,
Pasini et al. 2003, Byers, Wang et al. 2012, Coe, Thu et al. 2013). EZH2 has also
been identified as downstream of MEK-ERK-ELK1 pathway (Fujii, Tokita et al.
2011). Phosphorylation of transcription factor ELK1 by ERK leads to ELK1 binding
to the promoter of EZH2 gene, thereby activating EZH2 transcription. Regulation of
EZH2 overexpression by this pathway has been found in aggressive breast cancer
subtypes, such as triple-negative and HER2-overexpressing breast cancers (Fujii,
Tokita et al. 2011). Furthermore, hypoxia-inducible factor-1α (HIFα) directly
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regulates EZH2 transcription (Chang, Yang et al. 2011). Hypoxic condition in tumor
microenvironment stimulates HIFα binding to HIFα responsive element (HRE)
within the EZH2 gene promoter to upregulate EZH2 expression. Myc activates
EZH2 transcription through either binding to EZH2 promoter (Koh, Iwata et al. 2011)
or downregulating microRNAs (miR-26a and miR-101) (Sander, Bullinger et al.
2008, Koh, Iwata et al. 2011, Wang, Zhang et al. 2014). Transcription factors ETS,
NF-YA, STAT3, and fusion oncoprotein EWS-FLI1 also directly regulates EZH2
transcription in prostate, ovarian, colorectal cancers, and Ewing’s sarcoma,
respectively (Richter, Plehm et al. 2009, Kunderfranco, Mello-Grand et al. 2010,
Garipov, Li et al. 2013, Lin, Ren et al. 2013).
EZH2 expression are also regulated by post-transcriptionally (Yamaguchi and
Hung 2014). Several microRNAs (miRs) are responsible for this regulation. These
microRNAs directly downregulate EZH2 transcription through binding to the three
prime untranslated region (3’-UTR) of EZH2 gene. The increased expression of
EZH2 led by the loss of these microRNAs has been found in various cancers and
seems to be associated with aggressive disease. miR-101 is the first microRNA
identified to regulate EZH2 expression (Varambally, Cao et al. 2008). This
regulation was initially detected in prostate cancer and has later been found to be
involved in many other cancers, such as transitional cell carcinoma of bladder,
glioblastoma multiforme, and non-small cell lung cancer (Friedman, Liang et al.
2009, Smits, Nilsson et al. 2010, Zhang, Guo et al. 2011). Other microRNAs
mediating EZH2 expression in cancer include miR-25, -26a, -30d, -124, -137, -138,
-144, -214 and let-7 (Volkel, Dupret et al. 2015).
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In addition to transcription and post-transcription regulations, emerging
evidence shows that protein level and enzymatic activity of EZH2 are regulated by
post-translational modifications, such as phosphorylation and ubiquitination
(Yamaguchi and Hung 2014). These modifications lead to EZH2 degradation and
are critical for its protein stability and enzymatic activity. The first discovery of this
regulation is AKT1-mediated phosphorylation, in which EZH2 is phosphorylated at
Ser21 and phosphorylated EZH2 has altered affinity with histone H3 (Cha, Zhou et
al. 2005). EZH2 phosphorylation at Ser21 by AKT1 has later been shown to have
increased enzymatic activity in control of non-histone substrates, androgen
receptor and STAT3 (Xu, Wu et al. 2012, Kim, Kim et al. 2013). Cell cycle
regulators, cyclin-dependent kinase 1 and 2 (CDK1 and CDK2), phosphorylate
EZH2 at Thr487 and Thr416, respectively (Wei, Chen et al. 2011, Yang, LaBaff et
al. 2015). EZH2 phosphorylation at Thr478 by CDK1 disrupts PRC2 assembly and
decreases EZH2/PRC2 histone methyltransferase activity (Wei, Chen et al. 2011).
This regulation not only suppresses cell invasion and migration, but also enhances
osteogenic differentiation of human mesenchymal stem cells. CDK2-mediated
Thr416 phosphorylation augments cell migration, invasion and tumor growth, and
higher phosphorylation correlates with poor survival in triple-negative breast cancer
patients (Yang, LaBaff et al. 2015). CDK1/2-mediated phosphorylation of EZH2 has
also been identified by other groups with findings of different sites and effects
(Chen, Bohrer et al. 2010, Kaneko, Li et al. 2010, Wu and Zhang 2011, Minnebo,
Gornemann et al. 2013). Other kinases, including mitogen-activated protein kinase
p38α, Janus Kinase 2 (JAK2) and ataxia telangiectasia mutated (ATM), have been
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identified to phosphorylate EZH2 at different sites and are critical for the protein
stability, enzymatic activity and biological functions of EZH2 (Palacios, Mozzetta et
al. 2010, Li, Hart et al. 2013, Sahasrabuddhe, Chen et al. 2015). Several inhibitors
targeting kinases have been developed to treat human diseases like cancer. The
identification of EZH2 phosphorylation is significant not only because this regulation
controls EZH2 activity but also because it may provide clues for the development
of novel therapeutic strategies. Thus, to better understand how EZH2 is regulated
by phosphorylation is important.

1-5 Role of EZH2 in tumorigenesis
A number of studies have revealed that EZH2 is widespread implicated in
tumor development. The most manifest evidence is that high expression of EZH2
has been reported in multiple cancer types, including prostate cancer, breast
cancer, small cell and non-small cell lung cancers, endometrial carcinoma, ovarian
cancer, bladder cancer, renal cell carcinoma, gastric cancer, pancreatic cancer,
esophageal cancer, hepatocellular carcinoma, brain tumors and melanoma
(Varambally, Dhanasekaran et al. 2002, Kleer, Cao et al. 2003, Raman, Mongan et
al. 2005, Bachmann, Halvorsen et al. 2006, Matsukawa, Semba et al. 2006, Kondo,
Shen et al. 2007, McHugh, Fullen et al. 2007, Ougolkov, Bilim et al. 2008, Crea,
Hurt et al. 2010, Rao, Cai et al. 2010, Yamada, Fujii et al. 2011, Byers, Wang et al.
2012, Lee and Choe 2012, Behrens, Solis et al. 2013, Murai, Koinuma et al. 2015).
Higher expression of EZH2 is associated with aggressive and advanced diseases
and poor outcome in many of them (Varambally, Dhanasekaran et al. 2002, Kleer,
Cao et al. 2003, Bachmann, Halvorsen et al. 2006, Matsukawa, Semba et al. 2006,
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Crea, Hurt et al. 2010, Yamada, Fujii et al. 2011). Indeed, several studies have
demonstrated that EZH2 contributes to tumorigenesis through promoting malignant
transformation, cancer cell growth, invasion and migration. In noncancerous
epithelial cell lines, overexpression of EZH2 enhances in vitro anchorageindependent colony formation (Kleer, Cao et al. 2003, Karanikolas, Figueiredo et
al. 2009). In many types of cancer cells, EZH2 augments their invasion/migration
ability (Kleer, Cao et al. 2003, Rao, Cai et al. 2010, Wei, Chen et al. 2011, Moore,
Gonzalez et al. 2013, Xu, Hou et al. 2013, Han, Jiao et al. 2016), and some studies
have reported that EZH2 mediates invasion and/or migration by epigenetically
repressing tumor suppressor gene expressions through catalyzing trimethylation of
H3K27 (Yu, Cao et al. 2007, Cao, Yu et al. 2008, Du, Li et al. 2012, Ren, Baritaki
et al. 2012). Furthermore, in a tumorigenic mouse experiment using the mouse
mammary tumor virus (MMTV) long terminal repeat, EZH2 overexpression in
mammary epithelial cells induces intraductal epithelial hyperplasia phenotype (Li,
Gonzalez et al. 2009). Similarly, overexpression of EZH2 in benign prostate
epithelial cells leads to tumor growth in vivo (Karanikolas, Figueiredo et al. 2009).
All these investigations underline the critical role of EZH2 in tumorigenesis.
Gain-of-function mutations of EZH2 have been identified in B-cell lymphoma
(Morin, Johnson et al. 2010, Majer, Jin et al. 2012, McCabe, Graves et al. 2012).
Around 22% of diffuse large B-cell lymphoma and 7% of follicular lymphoma harbor
the recurrent somatic mutations of EZH2 at tyrosine 641 (Tyr641), which is located
within the catalytic SET domain (Morin, Johnson et al. 2010). In contrast to wildtype EZH2, Tyr641 mutant has higher methyltransferase activity to catalyze
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dimethylation and trimethylation of H3K27 but has lower activity to generate H3K27
monomethylation (Sneeringer, Scott et al. 2010, Yap, Chu et al. 2011). Subsequent
experiments using transgenic mice expressing EZH2Y641F in lymphocytes
demonstrated a significantly higher H3K27me3 level in spleen cells and developed
lymphomas when combined with Eµ-Myc expression, which validated the
observations and the oncogenic roles of this mutant (Berg, Thoene et al. 2014).
Additional studies have also identified A677G and A687V activating mutations with
higher enzymatic activity for trimethylation of H3K27 in B-cell lymphoma (Majer, Jin
et al. 2012, McCabe, Graves et al. 2012). These evidence further supports the
oncogenic role of EZH2 and activating mutations functioning as EZH2
overexpression highlights the importance of its histone methyltransferase activity in
EZH2-mediated oncogenesis.
Cancer stem cell (CSC) hypothesis has been proposed for decades (Dick
2008). Cancer stem cells represent a small portion of tumor population, which are
postulated to be responsible for cancer initiation, progression and metastasis. They
share features of normal stem cells, including self-renewal and multiple lineage
differentiation capacity, and may account for drug resistance. EZH2 has been
demonstrated to be essential in the maintenance of self-renewal and other
properties of embryonic and adult stem cells (Cao and Zhang 2004, Ezhkova,
Pasolli et al. 2009). Several studies have also found that EZH2 is not only frequently
overexpressed in a wide range of cancers, but also associated with an aggressive
and advanced disease, and has been linked to neoplastic transformation, cancer
cell migration/invasion and tumor development as aforementioned. An integrative
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analysis using genome-wide screening approach displayed that a significant group
of PRC2 target genes in cancer are also PRC2 targets in embryonic stem cells, and
repression of these genes correlates with worse outcome (Yu, Cao et al. 2007). It
has therefore been speculated that EZH2 is implicated in cancer stem cell biology.
Indeed, in breast tumor initiating cells, increased EZH2 expands cell population
through repressing RAD51 expression while knockdown of EZH2 reduces the
repression of RAD51 transcription by decreasing H3K27 trimethylation (Chang,
Yang et al. 2011). Similarly, EZH2 has been revealed to promote stem-like cell
properties in glioblastoma multifore and skin cancer, which are related to its
enzymatic activity or increased H3K27 trimethylation (Kim, Kim et al. 2013,
Adhikary, Grun et al. 2015).
HOX genes are well-known EZH2 target genes, which are vital in embryonic
development (Boyer, Plath et al. 2006, Lee, Jenner et al. 2006). In addition to HOX
genes, several genes have been identified in cancer and the majority of them are
tumor suppressors as EZH2 functions primarily as a tumor promoter. The INK4AARF-INK4B locus, encoding tumor suppressor p16INK4A, is controlled by
EZH2/PRC2 as well as BMI1. Its downregulation increases cell proliferation and is
critical in stem cell biology and cancer (Bracken, Kleine-Kohlbrecher et al. 2007,
Ezhkova, Pasolli et al. 2009). E-cadherin, a key mediator in epithelial-mesenchymal
transition (EMT) and metastasis, is also regulated by EZH2 and repression of Ecadherin gene expression (CDH1) enhances cell migration and metastasis in
several types of cancers (Cao, Yu et al. 2008, Fujii and Ochiai 2008, Wang, Liu et
al. 2013). In nasopharyngeal carcinoma, EZH2 forms a complex with Snail and
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HDAC1/HDAC2 to repress E-cadherin transcription, thereby promoting cell
aggressiveness (Tong, Cai et al. 2012). Moreover, there are several EZH2 target
genes involved in EZH2-mediated cancer progression, many of them are related to
invasion or migration. These include FOXC1 and RKIP in breast cancer, DAB2IP,
SLIT2, ADRBP2, TIMP-2 and TIMP-3 in prostate cancer, and their expression is
repressed by EZH2-mediated H3K27 trimethylation (Chen, Tu et al. 2005, Yu, Cao
et al. 2007, Yu, Cao et al. 2010, Du, Li et al. 2012, Ren, Baritaki et al. 2012, Shin
and Kim 2012). In addition, RAD51, CDKN1C (p57KIP2), RUNX3, KLF2 and IKKα
genes are also targeted by EZH2, and their repression mediated by H3K27me3 is
involved in cell proliferation, growth and differentiation in distinct cancer types,
respectively (Fujii, Ito et al. 2008, Yang, Karuturi et al. 2009, Chang, Yang et al.
2011, Taniguchi, Jacinto et al. 2012, Yan, Zhang et al. 2014).

1-6 EZH2 and breast cancer
Breast cancer is the most prevalent malignancy and the second leading
cause of cancer-related mortality among women in the United States. Based on
most recent statistics, approximately 246,660 of new invasive breast cancer
patients and 40,450 breast cancer mortality are expected among women in 2016
(Siegel, Miller et al. 2016). The mortality rate of breast cancer has been declining
since 1989 and the 5-year survival rate is 89% at present in all stages combined;
however, in breast cancer patients with distant metastasis, the 5-year survival rate
falls to 26% (Siegel, Miller et al. 2016). Almost all cancer deaths result from local
invasion and distant metastasis of tumor and patients with cancer metastasis is
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undoubtedly associated with worse prognosis. Therefore, a better understanding of
metastasis is critical.
As previously described, higher EZH2 expression has been correlated with
aggressive disease and poor outcome in breast cancer patients (Kleer, Cao et al.
2003). Ectopic expression of EZH2 in transgenic mouse model induces mammary
epithelial hyperplasia (Li, Gonzalez et al. 2009). Several studies indicated that
EZH2 promotes invasive and metastatic potential in breast cancer, many of them
validates that this regulation is mediated by repression of tumor suppressors
through EZH2 catalyzing trimethylation of H3K27, such as E-cadherin, FOXC1 and
RKIP (Cao, Yu et al. 2008, Du, Li et al. 2012, Ren, Baritaki et al. 2012). Indeed, an
investigation of immunohistochemial staining in human breast tumor specimens
also showed that EZH2 expression is upregulated in metastatic tissues (Moore,
Gonzalez et al. 2013).These evidence suggests that EZH2 acts as a tumor
promoter in breast cancer, and plays an important role in breast cancer metastasis.

1-7 EZH2 is a potential substrate of GSK3
In the process of tumorigenesis, inactivation or loss of function of tumor
suppressors is a crucial step. As mentioned previously, EZH2 activity can be
mediated kinases. However, the regulation of EZH2 activity by tumor suppressor
kinase in cancer is not fully understood. Interestingly, we noticed that EZH2 amino
acid sequence contains several GSK3 phosphorylation motifs (Ser/Thr-X-X-XSer/Thr, where X represents any amino acid) (Doble and Woodgett 2003),
suggesting that EZH2 might be regulated by GSK3 (Figure 1-1).
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Figure 1-1. GSK3 consensus motif in EZH2 amino acid sequence

1-1.

EZH2 amino acid sequence contains GSK3 phosphorylation motif.

The region of amino acid sequence of EZH2 containing GSK3 phosphorylation
motif is highlighted in yellow, in which possible phosphorylation serine/threonine
residues is marked in red.
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1-8 GSK3: its regulation and action
Glycogen

synthase

kinase

3

beta

(GSK3)

is

a

multifunctional

serine/threonine kinase. GSK3 was originally found in mammalian skeletal
muscle, responsible for phosphorylation of glycogen synthase, leading to its
inactivation in glycogen metabolism (Frame and Cohen 2001). It has later been
identified as a critical mediator of various signaling pathways involved in multiple
physiological processes, such as transcription, protein synthesis, cell cycle,
apoptosis, cell motility, and immune cell regulation (Grimes and Jope 2001, Doble
and Woodgett 2003, Sutherland 2011). In addition to GSK3, there is an isoform in
human, GSK3. GSK3 and GSK3 are 51 and 47 KDa proteins, encoded by
GSK3A and GSK3B genes, respectively. Although these two isoforms have similar
structure and overlapping functions, they are not redundant (McCubrey, Steelman
et al. 2014). GSK3 knockout mice are embryonically lethal, whereas GSK3
knockout mice are not (Hoeflich, Luo et al. 2000, MacAulay, Doble et al. 2007).
Owing to its extensive involvement in cellular functions, the deregulation of GSK3
has

been

implicated

in

a

wide

range

of

human

diseases,

including

neurodegenerative disorder, cardiovascular disease, diabetes mellitus, bipolar
disorder, and inflammation/immune disease (Grimes and Jope 2001, Sutherland
2011). Aberrations in GSK3 regulation also contribute to cancer initiation and
progression (Luo 2009, McCubrey, Steelman et al. 2014).
GSK3 is generally active in resting cells but becomes inactive upon external
signals (Grimes and Jope 2001). The activity of GSK3 is controlled by site-specific
phosphorylation through extracellular stimuli or signaling pathway (Medina and
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Wandosell 2011). GSK3 phosphorylation at Tyr216 associates with an increases
of its enzymatic activity. Tyr216 phosphorylation can be mediated by kinases such
as proline-rich tyrosine kinase 2 (PYK2), but may be due to autophosphorylation as
GSK3 is constitutively active at rest (Hartigan, Xiong et al. 2001, Cole, Frame et
al. 2004). GSK3 phosphorylation at Ser9 results in its inactivation via proteasomal
degradation (Medina and Wandosell 2011). Several kinases mediating this
regulation include protein kinase A (PKA), protein kinase B (also known as Akt),
certain isoform of protein kinase C (PKC), p90 ribosomal S6 kinase (p90RSK), and
p70 ribosomal S6 kinase (S6K1) (McCubrey, Steelman et al. 2014). A number of
factors, such as insulin, epidermal growth factor and transforming growth factor,
and some signaling pathways, like insulin signaling, mitogen-activated protein
kinase (MAPK)/p90RSK, or mTOR/S6K pathways can inactivate GSK3 through
this modulation (Ding, He et al. 2007). Our previous work also found that ERK
contributes this regulation (Ding, Xia et al. 2005). ERK phosphorylates GSK3 at
Thr43 residue, which facilitates Ser9 phosphorylation by p90RSK, leading to its
inactivation. These studies suggest that Ser9 phosphorylation is probably the most
important mechanism to control GSK3 activity (Luo 2009). In addition, this
modification has also been utilized as a measurement for GSK3 inactivation (Ding,
He et al. 2007).
Numerous proteins, such as EMT regulator SNAIL (Zhou, Deng et al. 2004)
and antiapoptotic protein MCL-1 (Ding, He et al. 2007), have been identified as
substrates of GSK3 and these substrates are implicated in an extensive spectrum
of cellular functions, suggesting that GSK3 is a fundamental regulators in cells
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(Sutherland 2011). GSK3 usually suppresses the function or activity of its
substrates via phosphorylation, meaning that these substrates are inactive or
inaccessible under unstimulated conditions (Grimes and Jope 2001, Sutherland
2011). One of the well-known substrate of GSK3 is -catenin. -catenin is the key
molecule of WNT/-catenin signaling pathway (Wu and Pan 2010). Without
stimulation, -catenin exists in the cytosol and forms a complex with Axin,
adenmatous polyposis coli (APC) and GSK3. GSK3 phosphorylates -catenin,
thereby resulting in degradation and inactivation of -catenin. Once the pathway is
stimulated, GSK3 is inactivated, which in turn prevents -catenin phosphorylation
and degradation in the cytosol, and subsequently leading to its nuclear translocation
and downstream target gene activation. Not all substrates of GSK3 are degraded
after being phosphorylated, but most of them are inactivated through this regulation.
In addition, the amino acid sequence of GSK3’s substrates usually contains a
phosphorylation motif, that is Ser/Thr-X-X-X-Ser/Thr, where X represents any
amino acid (Sutherland 2011). This motif is found in several substrates of GSK3,
such as glycogen synthase, -catenin, SNAIL and MCL-1 (Frame and Cohen 2001,
Liu, Li et al. 2002, Zhou, Deng et al. 2004, Ding, He et al. 2007).

1-9 Role of GSK3 in tumorigenesis
GSK3 has been shown to phosphorylate and inactivate many oncoproteins
or cell cycle regulators, and is a negative mediator of WNT/-catenin signaling
pathways, suggesting that GSK3 functions as a tumor suppressor in
carcinogenesis (Luo 2009). In an in vitro soft agar assay and an in vivo model of
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skin tumorigenesis, overexpression of wild-type or active form (S9A mutant) GSK3
reduces anchorage-independent growth of cells combined with treatment of
epidermal growth factor or chemicals and attenuates tumorigenicity; in contrast,
kinase-inactive form GSK3 enhances colony formation and tumor growth (Ma,
Wang et al. 2007). Similarly, this effect has been observed in mammary tumor
development. Overexpression of kinase-inactive form GSK3 in transgenic mice
using the mouse mammary tumor virus-long terminal repeat promotes mammary
tumorigenesis (Farago, Dominguez et al. 2005). Our group also demonstrated that
in tumor-bearing mice, activation of GSK3 by intratumor injection of the liposome
complex with GSK3 reduces mammary tumor growth (Ding, He et al. 2007). These
results imply that inactivation of GSK3 is a significant contribution factor for the
process of tumor development in these cancers. In addition to its role in neoplastic
cell transformation and tumor development, GSK3 is also involved in cancer
metastasis.

Epithelial—mesenchymal

transition

(EMT),

an

embryonically

developmental process, has been shown to play an essential role in promoting
metastasis in epithelial cancer (Tsai and Yang 2013). In non-small cell lung cancer,
GSK3 controls EMT and cancer metastasis via phosphorylation and degradation
of an EMT regulator, SLUG (Kao, Wang et al. 2014). Our previous work also found
that GSK3 negatively regulates EMT by phosphorylation of another EMT mediator,
SNAIL, in breast cancer (Zhou, Deng et al. 2004). Together, these evidence
indicates that GSK3 is an important regulator for tumorigenesis and cancer
metastasis.
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A number of studies have revealed that WNT/-catenin signaling pathway is
pivotal in control of embryonic development and adult cell fate and perturbations of
this pathway has been associated with maintenance of cancer stem cells and
subsequent tumorigenesis (Clevers 2006). Since GSK3 is a key regulator of
WNT/-catenin signaling pathway (Wu and Pan 2010), one would predict that
GSK3 is also involved in the regulation of cancer stem cell population (Benoit,
Guezguez et al. 2014). In chronic myeloid leukemia, a nonfunctional form of GSK3
has been detected in a subset of leukemia stem cells with aberrant activation of catenin, which contributes to leukemia stem cell generation and cancer progression
(Abrahamsson, Geron et al. 2009). This evidence links GSK3 to cancer stem cells
and further supports the importance of GSK3 inactivation in cancer. However,
studies investigating the direct role of GSK3 in cancer stem cell biology are limited.
Although aberrant WNT/-catenin signaling pathway has been shown to be related
to cancer epigenetics, the relationship between GSK3 and epigenetic regulators
in cancer remains unclear (Benoit, Guezguez et al. 2014).

1-10

Rationale for this study
Alterations in epigenetic mechanism, such as aberrant expression or

activation of epigenetic regulators, often induce neoplastic cell transformation and
tumor growth. EZH2, a histone methyltransferase, is the enzymatic core subunit of
PRC2 complex, which is responsible for catalyzing trimethylation of H3K27, leading
to epigenetically silencing of specific gene expression. Overexpression or activation
of EZH2 has been associated with several types of cancers and is related to
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aggressive disease and poor outcome. Studies have also demonstrated that EZH2
contributes to tumorigenesis through promoting malignant transformation, cell
proliferation, invasion and migration. The histone methyltransferase activity of
EZH2 plays a critical role in these processes.
In the process of tumor development, inactivation of tumor suppressors is
always an important step. EZH2 expression can be controlled by phosphorylation.
However, the regulation of EZH2 activity by tumor suppressor kinase is not well
understood. Interestingly, we noticed that EZH2 amino acid sequence contains
GSK3 phosphorylation motifs, suggesting that EZH2 might be regulated by
GSK3.
GSK3 is a serine/threonine kinase. It also participates in neoplastic
transformation and tumor development. In breast cancer, it functions as a tumor
suppressor. Studies have shown that inactivation of GSK3 promotes tumor
growth. GSK3 also regulates epithelial-mesenchymal transition and cancer cell
metastasis. However, little is known about the role of GSK3 in epigenetic
regulation during tumor development. It is not clear whether GSK3 regulates EZH2
activity and functions. In this study, we proposed that GSK3 attenuates
tumorigenesis through phosphorylation of EZH2 and suppression its enzymatic
activity (Figure 1-2).
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Figure 1-2. Hypothesis: GSK3 may regulate tumorigenesis through
phosphorylation of EZH2

1-2

GSK3

may

regulate

EZH2’s

phosphorylation of EZH2
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Chapter 2
Materials and Methods
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2-1 Cell culture
All cell lines were obtained from ATCC (Manassas, VA) and their validation
was performed in Characterized Cell Line Core Facility, MD Anderson Cancer
Center. The cell lines used in this study include MDA-MB-231, BT549, MDA-MB435S, MDA-MB-468, MCF7, MCF12A, HeLa and HEK 293T cells. All cells except
MCF12A were grown in Dulbecco’s Modified Eagle’s Medium/F12 supplement
(DMEM/F12) supplemented with 10% heat inactivated fetal bovine serum (FBS),
and Penicillin/Streptomycin (100 U, 100 μg/ml) at 37°C in a humidified atmosphere
with 5% CO2. MCF12A cells were cultured in DMEM/F12 media supplemented with
5% horse serum, Penicillin/Streptomycin (100 U, 100 μg/ml), EGF (20ng/ml),
Hydrocortisone (0.5mg/ml), Cholera toxin (100ng/ml) and insulin (10g/ml). For
inhibiting or activating GSK3 activity, cells were treated with 40 mM lithium chloride
(Sigma) for 16 hr or 0.1 M staurosporine (Sigma) for 2 hr.

2-2 Transfection
Transfection of cells with DNA was performed with liposome. Cells were
seeded in 10-cm culture dish or 6-well plate one day before transfection. Upon
transfection, plasmid DNA and liposome were mixed in a 1:2 (w/v) ratio and diluted
in OPTI-MEM. The plasmid DNA-liposome mixture were then added into media in
cell culture dish or plate. After incubation for 4-6 hrs, media containing DNAliposome mixture were replaced with fresh regular media. Transfected cells were
harvested for analysis or exploited for other experiments 48 hrs after transfection.
For generation of stable transfectants, the lentiviral-based pCDH or shRNA was
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used. To generate lentivirus expressing pCDH for EZH2 expression or shRNA for
GSK3 knockdown, HEK 293T cells were transfected with pCMV- ∆R8.92, pCMVVSVG plus EZH2, GSK3 or vector control plasmids. Media were change 6 hrs
after transfection, then were collected 48 hr and 72 hr after first media change. The
collected media containing lentivirus were filtered with 0.45-μm filters to remove cell
debris. Target cells were prepared before infection and collected media were added
into these cells at around 50% density. The media of infected cells were changed
24 hr after infection. Infected cells were selected by either G418 (Fisher) or
puromycin (Invivogen). EZH2 expressing and GSK3 knockdown stable
transfectants were validated by western blot analysis.

2-3 Whole cell lysis and subcellular fractionation
For whole cell lysis, 80 ~ 90% confluent cells were washed with cold PBS
buffer twice and lyzed with modified RIPA buffer (50 mM Tris-HCl at pH 7.6, 150
mM NaCl, 1% NP-40, 0.1% SDS) supplemented with 25 mM NaF, 2 mM Na3VO4
and protease inhibitor cocktail (1:100 dilution, Biotool). Lyzed cells were then
harvested, sonicated and centrifuged. The supernatant after centrifugation was
collected as cell lyate and its protein concentration was determined by Bio-Rad
protein assay kit (Pierce) using bovine serum albumin (BSA) as a standard.
For subcellular fractionation, cells were washed and firstly lyzed with Nori
buffer (20 mM HEPES at pH 7.0, 10 mM KCl, 2 mM MgCl2, 0.5% NP-40)
supplemented with 25 mM NaF, 2 mM Na3VO4 and protease inhibitor cocktail
(1:100 dilution, Biotool). After incubation for 30 min, the lyzed cells were
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homogenized by Dounce homogenizer for 30 strokes. Homogenized samples were
then centrifuged. The supernatant part was saved as non-nuclear (or cytosolic)
fraction. The rest part was further lyzed with modified RIPA buffer (50 mM Tris-HCl
at pH 7.6, 150 mM NaCl, 1% NP-40, 0.1% SDS) supplemented with 25 mM NaF, 2
mM Na3VO4 and protease inhibitor cocktail. The nuclear fraction was harvested
after sonication and centrifugation. Protein concentration was then determined.

2-4 Western blot and immunoprecipitation
For western blot analysis, cell lysate samples were diluted in sample buffer
and denatured by heating at 95 ºC for 5 min. Equal amount of cell lysates in same
volume was subjected into SDS-polyacrylamide gel electrophoresis. Proteins
separated by SDS-PAGE were then transferred onto PVDF membrane. After
blocking with non-fact 5% milk/TBST, PVDF membrane was incubated with primary
antibodies at 4 ºC for overnight and subsequently incubated with HRP secondary
antibody at room temperature for 1hr. After wash, PVDF membrane was shortly
immersed in enhanced chemiluminescence (ECL) solution mixture. The signals on
PVDF membrane were visualized by developing on autography film. Quantification
of the band density of target proteins in western blot experiments was analyzed by
free software ImageJ.
For immunoprecipitation assay, the protein amount of cell lysates and
antibody were used at a ratio of 1mg: 5g for each reaction. Cell lysates were
incubated with immunoprecipitation antibodies at 4ºC overnight, followed by
addition with 50 l of 50% protein G sepharose beads per 1 mg cell lysates and
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continuous incubation for 4 hr. After washed with modified RIPA buffer without 0.1%
SDS three to five times, beads were suspended in sample buffer and boiled at 95
ºC for 5 min. Immunoprecipitates were then subjected into SDS-polyacrylamide gel
and analyzed by western blotting.

2-5 Antibodies and phosphorylation antibody generation / screening
The

following

antibodies

were

used

in

western

blotting

and

immunoprecipitation: EZH2, phospho-GSK3 Ser9, trimethyl-H3K27, dimethylH3K27 and histone H3 (Cell Signaling Technology); monomethyl-H3K27 (EMD
Millipore), GSK3 (BD Biosciences); dephospho--catenin (Ezno Life Sciences);
Tubulin and Actin (Sigma); Lamin B1 (Abcam); Myc and HA (Roche). The mouse
phospho-EZH2 Ser363 and phospho-EZH2 Thr367 antibodies were produced
against the synthetic peptides RLPNNS(pS)RPSTPTI and SRPS(pT)PTINVLESKD
at China Medical University Hospital in Taiwan, respectively. The synthetic peptides
were obtained from LifeTein LLC. Twenty mice were immunized for each
phosphorylation antibody generation. Each mouse has been injected with phosphopeptide (hot peptide) for five times. After immunization, eighteen mouse sera
against Ser363 phosphorylation and twenty sera against EZH2 Thr367
phosphorylation were obtained. All mouse sera were screened by dot blot analysis
using corresponding phosphorylated (hot) and nonphosphorylated (cold) peptide
(Figure 2-1 and 2-2).
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Figure 2-1. Dot blot analysis of mouse antisera generated for Ser363
phosphorylation polyclonal antibody
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Figure 2-1. Dot blot screening for mouse sera against phospho-EZH2 Ser363
peptide.
Dot blot analysis was performed using PVDF membrane. Phospho-EZH2 at
Ser363 (hot) and non-phospho-EZH2 at Ser363 (cold) peptides (100ng/5ul/each)
were spotted on the membrane as illustrated. Each membrane containing hot and
cold peptides was incubated with various mouse antiserum (1:2000 dilution in 5%
BSA/TBST) as marked at 4 ºC overnight. After incubation with mouse secondary
antibody and ECL, the signals on PVDF membrane were acquired using the
ImageQuant LAS 4000 mini system (GE Healthcare Life Science, Pittsburgh, PA).
In this screening, only #5 and #7 mouse sera were able to distinguish hot
peptide from cold one. These two antisera were tested in a subsequent in vitro
kinase assay. Mouse antiserum #7 nonspecifically recognized phosphorylated wildtype GST-EZH2, GST-EZH2S363A and GST-EZH2T367A (data not shown). The test
result of #5 antiserum is shown in Figure 3-2J.
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Figure 2-2. Dot blot analysis of mouse antisera generated for Thr367
phosphorylation polyclonal antibody
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2-2. Dot blot screening for mouse sera against phospho-EZH2 Thr367 peptide.
Dot blot analysis was performed using PVDF membrane. Phospho-EZH2 at
Thr367 (hot) and non-phospho-EZH2 at Thr367 (cold) peptides (100ng/5ul/each)
were spotted on the membrane as illustrated. Each membrane containing hot and
cold peptides was incubated with various mouse antiserum (1:2000 dilution in 5%
BSA/TBST) as marked at 4 ºC overnight. After incubation with mouse secondary
antibody and ECL, the signals on PVDF membrane were acquired using the
ImageQuant LAS 4000 mini system.
The screening shows that many of mouse sera were able to distinguish Thr
367 EZH2 hot peptide from cold one. Some of them were tested in an in vitro kinase
assay. Mouse antiserum #7 was the best one and its test result is shown in Figure
3-2K.
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2-6 qRT-PCR
Total RNA was extracted from cells for qRT-PCR assays. Cells were washed
with PBS twice and lyzed in TRIzol (Life Technologies). Phase separation of lyzed
sample was carried out by chloroform and colorless aqueous phase of sample were
collected. RNA was then precipitated by isopropyl alcohol, washed with 75%
ethanol and dissolved in DEPC-treated water. cDNA was synthesized for
measurement of mRNA expression from extracted total RNA using SuperScript III
First-strand synthesis system by random hexamers (Life Technologies) following
the manufacturer’s protocol. Quantitative real-time PCR (qRT-PCR) was performed
using SYBR Green dye on a qRT-PCR machine (iQ5, BioRad, CA, USA). GAPDH
mRNA expression was used as internal control. The primer sequences used for
analysis of HOXA gene expression was listed in Table 2-1.
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Table 2-1. Primers for qRT-PCR
Table 2-1. Primers for qRT-PCR
Gene name Forward primer
HOXA2
ACAGCGAAGGGAAATGTAAAAGC
HOXA3
TGCAAAAAGCGACCTACTACGA
HOXA7
CAAAATGCCGAGCCGACTT
HOXA9
CCGAGAGGCAGGTCAAGATC
HOXA13
AAATGTACTGCCCCAAAGAGCA
GAPDH
TCCACTGGCGTCTTCACC
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Reverse primer
GGGCCCCAGAGACGCTAA
CGTCGGCGCCCAAAG
TAGCCGGACGCAAAGGG
AAATAAGCCCAAATGGCATCA
ATCCGAGGGATGGGAGACC
GGCAGAGATGATGACCCTTTT

2-7 Plasmids
Plasmids of HA-GSK3-WT (wild-type), HA- GSK3-CA (constitutively active,
S9A GSK3), and HA- GSK3-KD (kinase dead, K85R GSK3) were described
previously (Ding, He et al. 2007). pCDNA3-Myc-EZH2 was a gift from A.
Chinnaiyan. For EZH2 stable transfection, two EZH2 constructs were generated.
Myc-EZH2 was subcloned into the vector of pCDH-CMV-MCS-EF1-Puro (System
Biosciences), and Flag-EZH2 was subcloned into the vector of pCDH-CMV-MCSEF1-Neo (System Biosciences). To generate constructs for bacterial expression of
GST-tagged EZH2, two truncations were made in GST-EZH2 fusion protein format
in pGEX-6P1 vector (Amersham Biosciences or GE Healthcare). One EZH2
truncation, N-terminal fragment, was from amino acid residues 1-385, and another,
C-terminal fragment, was from 386-746. Site-directed mutagenesis was performed
to generate mutant EZH2 according to a protocol (Liu and Naismith 2008). Primers
used for mutagenesis were provided in Table 2-2. GSK3 knockdown was carried
out by pGIPZ-shRNA with the target sequence of 5´-TACTTGACAGTTCTTGAGT3´ (CDS, Clone ID V3LHS_309039, shRNA core facility, MD Anderson Cancer
Center).
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Table 2-2. Primers for site-directed mutagenesis
Table 2-2. Primers for mutagenesis
Target
Forward primer
S362A
CAATAACGCTAGCAGGCCCAGCACCCCCAC
S363A
CAATAACAGTGCCAGGCCCAGCACCCCCAC
S366A
CCCGCCACCCCCACCATTAATGTGCTGGAATC
T367A
CCCAGCGCCCCCACCATTAATGTGCTGGAATC
2A
GCCAGGCCCAGCGCCCCCACCATTAATGTGCTG
S363E
CAATAACAGTGAAAGGCCCAGCACCCC
T367E
CCCAGCGAACCCACCATTAATGTGCTG
2E
GAAAGGCCCAGCGAACCCACCATTAATGTGCTGG
S363D
CAATAACAGTGACAGGCCCAGCACCCC
T367D
CCCAGCGACCCCACCATTAATGTGCT
2D
GACAGGCCCAGCGACCCCACCATTAATGTGCTG
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Reverse primer
CCTGCTAGCGTTATTGGGAAGCCGTCCTCTTC
CCTGGCACTGTTATTGGGAAGCCGTCCTCTTC
GGGGGTGGCGGGCCTGCTACTGTTATTGGG
GGGGGCGCTGGGCCTGCTACTGTTATTGGG
GGCGCTGGGCCTGGCACTGTTATTGGGAAGCCGTC
CCTTTCACTGTTATTGGGAAGCCGT
GGGTTCGCTGGGCCTGCTACTG
TTCGCTGGGCCTTTCACTGTTATTGGGAAGCCGTC
CCTGTCACTGTTATTGGGAAGCCGT
GGGGTCGCTGGGCCTGCTACTG
TCGCTGGGCCTGTCACTGTTATTGGGAAGCCGTC

2-8 in vitro kinase assay
Recombinant, active GSK3 kinase was obtained from Life Technologies and
glutathione-S-transferase (GST)-fused full length EZH2 was purchased from BPS
Bioscience. GST-EZH2 C-terminal, wild-type and mutant GST-EZH2 N-terminal
fragments were purified from bacteria. For the GSK3 in vitro kinase assay, active
GSK3 kinase was incubated with wild-type or mutant GST-EZH2 purified proteins
in kinase buffer (50 mM Tris-HCl at pH 7.6, 10 mM MgCl2, 2 mM DTT and 0.1 mM
EDTA) in the presence of 5 μCi of [γ-32P] ATP and 50 μM cold ATP with substrates
at 30 °C for 30 min. Reaction mixtures were then subjected to SDS-PAGE, and
32P-labelled proteins were detected by autoradiography.

2-9 GST protein purification
GST-EZH2 N-terminal and C-terminal fragment proteins were purified using
BL21 E.coli. BL21 competent cells were transformed with plasmids encoding GSTEZH2 N-terminal or C-terminal fragments. After heat shock, transformed cells were
plated on Ampicillin-containing LB-Agar plate and incubated at 37 °C for overnight.
Next day, one single colony from each GST-EZH2 transforming clone growing on
LB-Agar plate was picked up and continued to grow in one 10-cm culture tube with
5 ml of Ampicillin-containing LB medium at 37 °C and 200 rpm shaking for
overnight. The 5-ml bacterial culture was diluted into 45 ml of LB medium next day
and continued to grow in the same condition until an OD value of 0.5 is reached.
IPTG Isopropyl β-D-1-thiogalactopyranoside (IPTG) was then added into 50-ml
bacterial culture at a concentration of 0.2mM for protein induction. The bacterial
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culture was incubated at 30 °C and 200 rpm. After 3 hr, the bacterial culture was
centrifuged at 6000 rpm for 15 min. The bacterial pellets were collected and lyzed
in RIPA buffer containing cocktail protease inhibitor, 1mM lysozyme, 1mM DNase
and 1mM DTT. After sonication and centrifugation, the supernatant from lyzed
bacterial pellets was collected and protein concentration was determined by protein
assay kit using BSA as a standard. To extract GST proteins, the supernatant was
incubated with GST beads at a ratio of 100ul/5mg (beads/proteins) at 4°C for 2 hr.
GST-EZH2 proteins were eluted from GST beads with 20mM glutathione at 4°C.
The eluents were subjected into SDS-PAGE, followed by Coomassie blue staining
for quantification.

2-10 Mass spectrometry analysis
To identify phosphorylation sites of EZH2, mass spectrometry analysis was
performed as previously described (Wei, Chen et al. 2011). Briefly, truncated GSTEZH2 purified proteins, GST-EZH2 N-terminal (a.a. 1-385) and C-terminal (a.a.
386-746) fragments, were incubated with GSK3 kinase in a kinase reaction
mixture at 30 °C for 30 min. After being resolved by SDS-PAGE, the protein band
corresponding to EZH2 was excised and subjected to digestion with trypsin. The
phosphopeptides were then isolated by immobilized metal affinity chromatography.
The micro-liquid chromatography/tandem mass spectrometry (LC–MS/MS) was
used to analyze the phosphopeptides through an Ultimate capillary LC system (LC
Packings) coupled with a time-of-flight (TOF) mass spectrometer (Applied
Biosystems). Carbamidomethyl cysteine was used as the control modification,
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whereas serine, threonine, and tyrosine phosphorylation were set as variables. The
identified phosphopeptides were further validated via manual interpretation of the
product ion spectra from LC–MS/MS.

2-11 in vitro methylation assay
Lysates

of

cells

stably

expressing

Flag-tagged

wild-type

EZH2,

nonphosphorylable mutants, and phospho-mimic mutants were harvested. Flagtagged EZH2 proteins were purified by monoclonal anti-Flag M2 affinity agarose
beads (Sigma). For in vitro methylation assay, 30ul of beads containing Flag-EZH2
were mixed with 2ug of recombinant histone H3 (New England Biolabs) or
nucleosome (BPS Bioscience) and 1 mM of S-adenosylmethionine (SAM; New
England Biolabs) as methyl group donors in methylation buffer (50 mM Tris-HCl at
pH 8.0 and 10 mM DTT) and incubated at 30 °C for 1 hr. The supernatant of reaction
mixtures were resolved by 15% SDS-PAGE gel and immunoblotting with antibodies
against methylation of histone H3. The rest beads were suspended in sample
buffer, boiled at 95 ºC for 5 min, and subjected to SDS-PAGE for analysis of EZH2
protein expression.

2-12 3D soft agar and 2D clonogenic assays
For the soft agar colony formation assay, 2.5 × 104 cells were seeded in 1 ml
of regular medium with 0.5% low melting point agarose and overlaid on 1 ml of
medium with 1% agarose in each well of a six-well plate. After 3 weeks, colonies
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were fixed and stained with crystal violet. Colonies larger than 100 m in diameter
were counted under a microscope for quantitation.
For the clonogenic assay, 200 cells per well were seeded in a 6-well plate
and grown in regular medium for 10 days. Cell colonies were fixed and stained with
crystal violet, and then counted for quantitation.

2-13 Cell migration assay
The wound healing assay was performed using a culture-insert (ibidi GmbH,
Germany) according to manufacturer’s instruction. The culture-insert had two cell
culture reservoirs, which were separated by a 500 m-thick wall. Same numbers of
cells were seeded in the culture-insert. After 24 hr, the culture-insert was removed,
which left a cell-free “wound” of around 500 m in width. The wound closure was
observed by a time lapse microscopy (Zeiss, Germany) and images were obtained
at 1 h interval for 24 hr. The area of wound was analyzed using the ImageJ software
program.
Migration abilities were also determined using 24-well Boyden chamber
plates with an 8 μm pore size polycarbonate filter (BD Biosciences). 1 × 105 cells
were seeded into upper chambers with serum-free medium. Lower chambers
contained 10% FBS medium. After incubation at 37 °C for 24 h, chamber filters
were fixed and stained. Cells on the top of filters were removed. Numbers of
migrated cells were counted under a light microscopy.
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2-14 Animal experiment
Tumorigenesis assay was carried out using an orthotopic mouse model.
MCF12A cells with stable expression of EZH2-WT, EZH2-S363A, EZH2-T367A,
EZH2-2A, or EZH2-2E were exploited in the experiment. Two millions of each stable
line were injected into the mammary fat pads of six-week-old nude mice (five mice
per group). Tumor size was measured twice a week with calipers, and tumor volume
was determined using the formula 0.5 x L x W2, where L is the longest diameter
and W is the shortest diameter. The animal protocol was reviewed with the approval
of the Institutional Animal Care and Use Committee (IACUC) at The University of
Texas MD Anderson Cancer Center. All animal procedures were performed
according to the regulations of the Division of Laboratory Animal Medicine at The
University of Texas MD Anderson Cancer Center.

2-15 Immunohistochemical staining
Immunohistochemical

(IHC)

staining

was

performed

using

an

immunoperoxidase-based staining method. One hundred and ten human breast
cancer tissue specimens were obtained from the Department of Pathology,
Shanghai East Breast Disease Hospital, Shanghai, P.R. China. Tissue microarray
(TMA) slides were prepared from the paraffin-embedded breast tumor samples.
Each specimen was stained with specific antibodies against pS9-GSK3 (Cell
Signaling Technology) and H3K27 trimethylation (EMD Millipore) and scored by an
H-score method as previously described (Ding, He et al. 2007). The intensity of
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staining based on histological scoring was ranked into: high (score 3), medium
(score 2), low (score 1), and negative (score 0). High and medium intensity of
staining were grouped into “high expression”. Low and negative were “low
expression”.

2-16 Statistical analysis
SPSS software (version 22, IBM) was used for statistical analysis. To analyze
categorical variables between the two groups, a Pearson -squared test was used
to examine the relationship between pS9-GSK3 expression and H3K27
trimethylation levels. A p-value of less than 0.05 is considered statistically
significant.
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Chapter 3
Results
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3-1 GSK3 negatively regulates H3K27 trimethylation
EZH2 is a histone methyltransferase and has been reported to modulate
tumor initiating cell expansion and cancer cell invasion, migration through
catalyzing trimethylation of H3K27 (Chang, Yang et al. 2011, Ren, Baritaki et al.
2012). EZH2 is highly expressed in many solid tumors (Bachmann, Halvorsen et al.
2006). Overexpression of EZH2 promotes malignant transformation and tumor
growth (Kleer, Cao et al. 2003, Karanikolas, Figueiredo et al. 2009). These
evidence suggests that EZH2 functions as a tumor promoter in carcinogenesis. In
addition, GSK3, a serine/threonine kinase, has been demonstrated to negatively
regulate neoplastic transformation and tumorigenesis (Luo 2009). It has also been
shown to control cancer cell metastasis through mediating inactivation of EMT
regulators (Zhou, Deng et al. 2004). Since EZH2 and GSK3 have common
functions in tumorigenesis, we speculated whether GSK3 regulates EZH2
expression or activity.
To investigate the regulation of EZH2 activity by GSK3, we first determined
whether alteration of GSK3 activity affects H3K27 trimethylation. We found that
inhibition of GSK3 by lithium chloride, a GSK3 inhibitor, increased H3K27
trimethylation expression in breast cancer and mammary epithelial cells, and
conversely, activation of GSK3 using the anticancer drug staurosporine reduced
the H3K27 trimethylation level in MDA-MB-468, MDA-MB-435S and BT549 cells
(Figure 3-1A). There was no change in EZH2 level. Consistently, knockdown of
GSK3 by small hairpin RNA enhanced trimethylation of H3K27 in HeLa cells
(Figure 3-1B). Exogenous expression of the wild type or constitutively active form
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GSK3 decreased H3K27 trimethylation expression in HeLa cells (Figure 3-1C).
HOX genes are well-known EZH2 target genes (Lee, Jenner et al. 2006). We
therefore examined the expression of EZH2 target genes in the HOXA family. We
found that lithium chloride downregulated the expression of many of HOXA genes
(Figure 3-1D). Together, these results suggested that GSK3 negatively regulates
the expression of H3K27 trimethylation and EZH2-targeted genes.
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Figure 3-1. GSK3 downregulates H3K27 trimethylation and EZH2 targeted
genes, HOXA genes.

A. Alteration of GSK3 activity changes H3K27 trimethylation. MDA-MB-231,
BT549, MDA-MB-468, MDA-MB-435S, and MCF12A cells were treated with lithium
chloride (LiCl), staurosporine (STS) as indicated. Cell lysates were subjected to
western blot analysis with the indicated antibodies. The intensities of H3K27me3
bands from treated cells were compared to those from untreated cells and the
relative ratios are shown.
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Figure 3-1

B. Inhibiting GSK3 by knockdown of GSK3

upregulates H3K27

trimethylation. HeLa cells were infected with lentiviruses expressing control or
GSK3 shRNA. Cells were lyzed and analyzed by immunoblot with antibodies
against indicated proteins. Relative intensitis of H3K27me3 bands are shown.
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Figure 3-1

C. Activating GSK3 activity by overexpression of wild-type of active GSK3
reduces H3K27 trimethylation. HeLa cells were transfected with the plasmids
encoding wild-type (WT), constitutively active (CA), kinase-dead (KD) GSK3 or
empty vector control. Equal amounts of cell lysates were analyzed by western blot
using antibodies against specific proteins. Relative intensities of H3K27me3 bands
are shown, normalized to the intensity of H3K27me3 band from HeLa cells
transfected with control plasmid.
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Figure 3-1

D. Inhibiting GSK3 activity by lithium chloride downregulates HOXA genes.
Left: Western blot analysis of lysates from MDA-MB-231 cells treated with PBS or
lithium chloride. Lysates were immunobloted with the indicated antibodies. Relative
intensities of H3K27me3 bands are shown. Right: qPR-PCR analysis of relative
mRNA expression of HOXA family genes in lysates from MDA-MB-231 cells treated
with PBS or lithium chloride. Data are expressed as mean ± s.d. (n = 3).
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3-2 GSK3 interacts with and phosphorylates EZH2
Several proteins have been found to be phosphorylated by GSK3 and
GSK3 usually attenuates the activity of its substrates by this regulation. GSK3 is
a serine/threonine kinase and has a preference for its substrates through
recognizing a phosphorylation motif, Ser/Thr-X-X-X-Ser/Thr, where X represents
any amino acid proteins (Sutherland 2011). Interestingly, we noticed that EZH2
amino acid sequence contains this motifs, suggesting that EZH2 is a potential
substrate of GSK3. Since altering GSK3 activity affects the trimethylation of
H3K27 and the expression of EZH2-targeted genes, we next investigated whether
GSK3 interacts with and phosphorylates EZH2. To address this possibility, we first
performed a co-immunoprecipitation experiment, which demonstrated an
association between endogenous GSK3 and EZH2 in MCF12A cells (Figure 32A). Because EZH2 functions primarily in nucleus and GSK3 exists mainly in the
cytosol, we further examined subcellular localization of their interaction. We
performed subcellular fractionation and found, indeed, EZH2 is predominantly
present in the nucleus, whereas GSK3 is found mostly in the cytosol (Figure 3-2B,
right panel). Surprisingly, we detected the GSK3-EZH2 interaction mainly in the
cytosol (Figure 3-2B, left panel). These results suggested that GSK3 physically
interacts with EZH2 in the cytosol.
Next, we examined whether GSK3 can phosphorylate EZH2. An in vitro
kinase assay revealed that GSK3 catalyzed the phosphorylation of EZH2 but not
glutathione-S-transferase (GST) (Figure 3-2C, lane 1-3). Mass spectrometry
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analysis using truncated GST-EZH2 N-terminal and C-terminal fragments identified
4 phosphorylation sites. On N-terminal fragment, two phosphorylation sites were
identified, one is either Ser362 or Ser363; another is Ser366 or Thr367 (Figure 32D). The rest 2 other sites were identified on C-terminal fragment, one is Thr386 or
Thr388 (Figure 3-2E), the other is Ser620 (Figure 3-2F). Since this phosphorylation
was catalyzed primarily on EZH2’s N-terminal fragment, rather than its C-terminal
fragment (Figure 3-2C, lane 4-6), we then focused on investigating the possible 4
sites identified on N-terminal fragment. We replaced these 4 residues with alanine
individually. An in vitro kinase assay demonstrated that the phosphorylation
catalyzed by GSK3 was reduced at the Ser363A mutant and was nearly
undetectable at the Thr367A mutant (Figure 3-2G), which suggests that these two
residues are GSK3 phosphorylation sites on EZH2. As Thr367A mutant totally
abolished GSK3 phosphorylation but Ser363 did not, we reasoned that Thr367
phosphorylation may be required for Ser363 phosphorylation. To test this
hypothesis, we generated phosphomimic Thr367 mutants, Thr367D and Thr367E.
We also generated a double A (Ser363A & Thr367A) mutant for further validation.
In the experiment of in vitro kinase assay, we did not observe the phosphorylation
catalyzed by GSK3 at the Thr367D and Thr367E mutants, but consistently, the
phosphorylation catalyzed by GSK3 was virtually undetectable in double A mutant
(Figure 3-2H). A search of National Center for Biotechnology Information (NCBI)
database using Basic Local Alignment Search Tool (BLAST) revealed that Ser363
and Thr367 of EZH2 are highly conserved across species (Figure 3-2I).
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To confirm the phosphorylation of EZH2 by GSK3 in vivo, we generated
specific mouse antisera against the phosphorylated EZH2 at Ser363 and Thr367
separately. After dot blot screening (Figure 2-1 and 2-2), we validated the specificity
of the antibody by an in vitro kinase assay using cold ATP. The mouse antiserum
generated

against

Ser363

phosphorylation

recognized

GSK3-catalyzed

phosphorylation on wild-type GST-EZH2; however, it also identified nonphosphorylated wild-type GST-EZH2 or GST-EZH2S363A mutant (Figure 3-2J),
suggesting that its specificity for Ser363 phosphorylation recognition is not good.
This antibody did not work in the following experiments, neither. For mouse antisera
against Thr367 phosphorylation, the antibody recognized the GSK3-catalyzed
phosphorylation on wild-type GST-EZH2 or GST-EZH2S363A mutant, but not the
nonphosphorylable GST-EZH2T367A mutant (Figure 3-2K), indicating that it can
specifically identify Thr367 phosphorylation of EZH2. Using this antibody, we found
that GSK3 enhanced the endogenous level of the phosphorylated EZH2 at Thr367
when GSK3was overexpressed in HeLa cells (Figure 3-2L). Taken together,
these data indicated that GSK3 phosphorylates EZH2 at Ser363 and Thr367.
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Figure 3-2. GSK3 physically associates with and phosphorylates EZH2

A. Endogenous interaction between GSK3 and EZH2. Cell lysates from
MCF12A cells were immunoprecipitated by either anti-GSK3 (right panel) or antiEZH2 (left panel) antibodies, then immunoblotted with indicated proteins.

57

Figure 3-2

B. GSK3 interacts with EZH2 mainly in cytosol. MCF12A cells were lyzed and
followed by cellular fractionation. Nuclear (Nuc) and cytosolic (Cyto) fractions were
immunoprecipitated with anti-EZH2 antibody and immunoblotted by antibodies
against EZH2 and GSK3. Lamin B1 and Tubulin were used as markers for nuclear
and cytosolic fractions respectively.
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Figure 3-2

C.GSK3 phosphorylates EZH2 in vitro, and GSK3 phosphorylation of EZH2
is primarily on EZH2 N-terminal fragment. in vitro kinase assay was performed
with recombinant, active GSK3 kinase and full-length GST-EZH2 (FL), GST-EZH2
N-terminal (a.a. 1-385; GST-EZH2-N), or C-terminal (a.a. 386-746; GST-EZH2-C)
fragment. The phosphorylation was detected by autoradiography. Loading amount
of different EZH2 proteins was accessed by coomassie blue staining.
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Figure 3-2

D. Mass spectrometry analysis of GSK3-phosphorylated GST-EZH2 Nterminal fragment. The samples from an in vitro kinase assay with GSK3 kinase
and GST-EZH2-N (a.a. 1-385) were used for mass spectrometry analysis. The
spectrum shows that two phosphorylation sites were identified; one is either T367
or S366 (marked in red), another is S363 or S362 (marked in green).
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Figure 3-2

E & F. Mass spectrometry analysis of GSK3-phosphorylated GST-EZH2 Cterminal fragment. The samples from in vitro kinase assays with GSK3 kinase
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and GST-EZH2-C (a.a. 386-746) were used for analysis. This analysis identified
two phosphorylation sites; one is either T386 or T388 (E), another is S620 (F).
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Figure 3-2

G. GSK3 phosphorylates EZH2 at Ser363 and Thr367. in vitro kinase assay
was carried out with active GSK3 kinase and wild-type GST-EZH2 N-terminal
fragment (WT), EZH2S362A-N EZH2S363A-N, EZH2S366A-N, or EZH2T367A-N. The
phosphorylation was examined by autoradiography. Loading of GST-EZH2 Nfragment was accessed by coomassie blue staining.
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Figure 3-2

H. Phospho-mimic T367-EZH2 does not facilitate GSK3 phosphorylation of
EZH2 in vitro. in vitro kinase assay was performed with active GSK3 kinase and
wild-type (WT) or mutant GST-EZH2 N-terminal fragments as indicated. The
phosphorylation was examined by autoradiography. Loading of EZH2 proteins was
accessed by coomassie blue staining. 2A represents S363A and T367A mutant.
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Figure 3-2

I. Comparison of GSK3 phosphorylation sites of EZH2 among various
species.
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Figure 3-2

J. S363 phosphorylation antibody recognizes non-phosphorylated EZH2 in
addition to Ser363 phosphorylation. Ser363 phosphorylation antibody was
tested using the samples from an in vitro kinase assay with active GSK3 kinase
and purified wild-type GST-EZH2-N (WT), GST-EZH2S363A-N or GST-EZH2T367A-N
in the presence of cold ATP at 30°C for 30 min. Reaction mixtures were analyzed
by western blot with mouse serum against Ser363 phosphorylation of EZH2 or
antibodies as indicated. Eighteen mouse sera against Ser363 phosphorylation were
screened by dot blot analysis. Two of them were able to distinguish phosphorylated
(hot) peptide from nonphosphorylated (cold) one. Only one can recognize Ser363
phosphorylation, which is shown here.
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Figure 3-2

K. Validation of Thr367 phosphorylation antibody. Thr367 phosphorylation
antibody was tested using the samples from an in vitro kinase assay with active
GSK3 kinase and purified wild-type GST-EZH2-N (WT), GST-EZH2S363A-N or
GST-EZH2T367A-N in the presence of cold ATP at 30°C for 30 min. Reaction
mixtures were analyzed by western blot with mouse serum against Thr367
phosphorylation of EZH2 or antibodies as indicated.
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Figure 3-2

L. GSK3 enhances endogenous T367 phosphorylation of EZH2. Cell lysates
from HeLa cells transfected with control or wild-type GSK3 were immunoblotted
with Thr367 phosphorylation antibody or specific proteins. Relative intensities of
Thr367 phosphorylation and H3K27me3 bands are shown, normalized to those
from HeLa cells transfected with control plasmid.

68

3-3 GSK3-mediated phosphorylation of EZH2 downregulates H3K27
trimethylation
Since GSK3 negatively regulates H3K27 trimethylation and phosphorylates
EZH2 at Ser363 and Thr367, we next investigated whether GSK3 phosphorylation
sites on EZH2 affects the expression of H3K27 trimethylation. MDA-MB-231 and
MCF12A cells were transfected with plasmids expressing the wild-type EZH2,
nonphosphorylable, or phospho-mimic mutants. In MDA-MB-231 cells, we
transfected with wild-type EZH2, EZH22A or EZH22E and found that EZH22A
increased H3K27 trimethylation levels and EZH22E decreased its expression
(Figure 3-3A). To examine the effects of individual phosphorylation sites on H3K27
trimethylation levels, MCF12A cells were expressed with EZH2S363A, EZH2T367A ,
EZH22A, or wild-type EZH2. In MCF12A stable cells, trimethylation of H3K27 was
upregulated in all nonphosphorylable mutants (Figure 3-3B). Consistently, we
observed the similar effects of phospho-mimic mutants on H3K27 trimethylation
levels in MCF7 (Figure 3-3C) and MCF12A (Figure 3-3D) cells expressing
EZH2S363E,

EZH2T367E,

or

EZH22E.

These

data

suggests

that

GSK3

phosphorylation sites on EZH2 inversely affects the expression of H3K27
trimethylation.
To validate whether these phosphorylation sites’ effect on the expression of
H3K27 trimethylation is modulated by GSK3 activity, HeLa cells were cotransfected with plasmids encoding constitutively active GSK3 plus wild-type
EZH2, or nonphosphorylable mutant EZH2 (EZH22A, EZH2S363A and EZH2T367A).
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We found that and GSK3 activation decreased the trimethylation of H3K27 in wildtype EZH2 but not in mutants (Figure 3-3E).
EZH2 is a histone methyltransferase and responsible for catalyzing
trimethylation of H3K27. To further examine whether EZH2 phosphorylation by
GSK3 changes the histone methyltransferase activity of EZH2, we performed an
in vitro methylation assay using recombinant histone H3 peptides as substrates.
Stable cells expressing wild-type and mutant Myc-EZH2 have been used for in vitro
methylation experiments but they did not work. Flag-tagged EZH2 construct was
then generated. NIH-3T3 cells were transfected with plasmids encoding wild-type
Flag-EZH2, nonphosphorylable (EZH22A, EZH2S363A and EZH2T367A) or phosphomimic mutants (EZH22E, EZH2S363E and EZH2T367E). In these EZH2 stable lines,
H3K27 trimethylation was consistently reduced in all phospho-mimic mutant EZH2
cells, and was, to a lesser extent, increased in nonphosphorylable mutants (Figure
3-3F, right panel). in vitro methylation assay revealed that monomethylation of
H3K27 catalyzed by phospho-mimic mutant EZH2 was reduced compared to that
by wild-type EZH2, and dimethylation (data not shown) or trimethylation of H3K27
catalyzed by either wild-type or mutant EZH2 was similar (Figure 3-3F, left panel).
EZH2 is able to catalyze methylation of histone H3 from monomethylation to
trimethylation step by step. This data may not be drawn a conclusion, but provides
a hint that GSK3 phosphorylation of EZH2 might suppress EZH2’s histone
methyltransferase activity.
As aforementioned, the association of EZH2 with SUZ12 and EED affects
EZH2’s histone methyltransferase activity. However, we did not observe an
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increased binding of EZH2 to SUZ12 or EED in MCF12A cells expressing
nonphosphorylable EZH2 (Figure 3-3G). Collectively, these data suggested that
GSK3-mediated

phosphorylation

of

EZH2

negatively

mediates

H3K27

trimethylation, implying that this regulation may affect EZH2’s enzymatic activity.
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Figure 3-3 GSK3-mediated phosphorylation of EZH2 suppresses H3K27
trimethylation.

A. GSK3 nonphosphorylable 2A mutant increases H3K27me3 level and
phospho-mimic 2E mutant decreases it in MDA-MB-231 cells. MDA-MB-231
cells were stably transfected with plasmids encoding wild-type EZH2, EZH22A,
EZH22E or empty vector control. Cell lysates were subjected to western blot analysis
using indicated antibodies. Relative intensities of H3K27me3 bands are shown,
compared to those from cells expressing wild-type EZH2. 2E represents Ser363E
and Thr367E.
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Figure 3-3

B. GSK3 nonphosphorylable mutants upregulates H3K27me3 level in
MCF12A cells. MCF12A cells were stably transfected with plasmids encoding wildtype EZH2, EZH22A, EZH2S363A, EZH2S367A, or control. Cell lysates were
immunoblotted with specific antibodies. Relative intensities of H3K27me3 bands
are presented.
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Figure 3-3

C & D. GSK3 nonphosphorylable 2A mutant enhances H3K27me3 level and
phospho-mimic mutants reduces it in MCF7 (C) and MCF12A cells (D). MCF7
and MCF12A cells were stably transfected with plasmids encoding wild-type EZH2,
EZH22A, EZH22E, EZH2S363E, EZH2T367E, or vector control. Cell lysates were
subjected to western blot analysis using indicated antibodies. Relative intensities of
H3K27me3 bands are shown, compared to those from cells expressing wild-type
EZH2. 2E represents Ser363E and Thr367E.
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Figure 3-3

E. GSK3 activation suppresses H3K27 trimethylation in wild-type EZH2 but
not in mutants. HeLa cells were co-transfected with plasmids encoding wild-type
or nonphosphorylable mutant Myc-EZH2 plus constitutively active form FlagGSK3. Cell lysates were subjected to western blot analysis with the indicated
antibodies.
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Figure 3-3

F. GSK3 phospho-mimic mutant EZH2 might have relatively lower histone
methyltransferase activity. NIH-3T3 cells were transfected with plasmids as
indicated. Whole cell lysates were collected and immunoblotted with specific
antibodies. For in vitro methylation assay, Flag-tagged EZH2 proteins were purified
by monoclonal anti-Flag M2 affinity agarose beads. in vitro methylation assay was
performed using purified Flag-EZH2 protein incubated with recombinant histone H3
and S-adenosylmethionine (SAM) as methyl group donors in methylation buffer at
30 °C for 1 hr. The supernatant of reaction mixtures were resolved by 15% SDSPAGE gel and immunoblotting with antibodies against methylation of histone H3.
The immunoprecipitate from the rest beads were subjected to SDS-PAGE for EZH2
expression.
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Figure 3-3

G. GSK3 phosphorylation of EZH2 does not affect the association of EZH2
with SUZ12 and EED. Cell lysates from MCF12A stable cells expressing wild-type
EZH2, EZH22A, EZH2S363A, EZH2T367A, or vector control were immunoprecipitated
with anti-Myc antibody, followed by immunoblotted with EZH2, SUZ12 and EED
antibodies (left panel). Input lysate was analyzed to detect the expression levels of
the indicated proteins (right panel).
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3-4 GSK3 nonphosphorylable mutants enhances EZH2’s oncogenic
functions
Because EZH2 is known to promote cell transformation and migration (Kleer,
Cao et al. 2003, Moore, Gonzalez et al. 2013), and GSK3-mediated
phosphorylation of EZH2 downregulates H3K27 trimethylation, we next studied the
effect of nonphosphorylable and phospho-mimic mutant EZH2 on EZH2-regulated
biological functions. As described previously, GSK3 tends to be constitutively
active in quiescent state and becomes inactive in response to extracellular signals
or in exciting state (Luo 2009). In contrast to noncancerous cells, GSK3 might be
relatively inactive in cancerous cells. To investigate the tumor promoting role of
EZH2 mediated by GSK3, we chose noncancerous mammary epithelial MCF12A
cells for following function assays in addition to breast cancer MDA-MB-231 cells.
Colony formation abilities and cell migration potentials were determined in
MDA-MB-231 stably transfected with wild-type EZH2, nonphosphorylable 2A or
phospho-mimic 2E mutant. There was no significant difference in cell proliferation
among all transfectants (Figure 3-4A). A soft agar assay revealed that
nonphosphorylable EZH2 (EZH22A) increased cell growth whereas phospho-mimic
mutant (EZH22E) had similar colony formation with wild-type EZH2 (Figure 3-4B).
Consistently, a wound healing assay monitored by time-lapse microscopy
demonstrated that nonphosphorylable mutant (EZH22A) enhanced cell migration
while EZH22E had similar rate of wound closure, compared to wild-type EZH2
(Figure

3-4C).

To

further

determine

the

effect

of

individual

single

nonphosphorylable mutants on the EZH2’s biological functions, we performed a soft
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agar and a wound healing experiments in noncancerous MCF12A mammary
epithelial cells stably expressing EZH2S363A, EZH2T367A, EZH22A mutants. The
results revealed that all nonphosphorylable EZH2 promoted cell growth in an
anchorage-independent manner as well as cell migration (Figure 3-4D and 3-4E).
A Boyden chamber migration assay also supported our previous observations
(Figure 3-4F). These results suggested that GSK3 inactivation promotes EZH2’s
oncogenic functions.
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Figure 3-4. GSK3nonphosphorylable mutant EZH2 promotes anchorageindependent growth and cell migration.

A. GSK3 nonphosphorylable or phospho-mimic mutant EZH2 does not affect
cell growth in 2D culture condition in MDA-MB-231 cells. Colony formation
abilities of MDA-MB-231 stable cell lines were determined using 2D clonogenic
assay. Cells were seeded in 6-well plates as described. The number of colonies
counted in one well of 6-well plate is shown as bar graphs. Data are expressed as
mean ± s.d. from three independent experiments. Representative images are
shown at the top of each bar graph.
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Figure 3-4

B. GSK3 nonphosphorylable 2A mutant promotes anchorage-independent
cell growth in MDA-MB-231 cells. Colony formation abilities of MDA-MB-231
stable cell lines were determined using soft agar assay. Cells were seeded in 6well plates as described. The number of colonies counted in one well of 6-well plate
is shown as bar graphs. Data are expressed as mean ± s.d. from three independent
experiments. Representative images are shown at the top of each bar graph.
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Figure 3-4

C. GSK3 nonphosphorylable 2A mutant enhances cell migration in MDA-MB231 cells. Migration potential of MDA-MB-231 stable cell lines were measured by
wound healing assay. Cells were seeded in culture inserts and migration was
observed by time-lapse microscope as described. Representative images of each
line are shown immediately (time 0), 12 h, and 18 h after removal of culture inserts.
The areas of wound gap at the indicated time points were determined using the
ImageJ software program and normalized to the area of wound gap at time 0.
Wound closures were calculated and are plotted as bar graphs. Data are mean ±
s.d. from three independent experiments.

82

Figure 3-4

D. GSK3 nonphosphorylable mutants promotes anchorage-independent cell
growth in MCF12A cells. The same experiments as described in A were
performed in MCF12A stable cell lines.
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Figure 3-4

E. GSK3 nonphosphorylable 2A mutant enhances cell migration in MCF12A
cells. The same experiments as described in B were performed in MCF12A stable
cell lines.
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Figure 3-4

F. GSK3 nonphosphorylable mutants enhances cell migration in MCF12A
cells determined by Boyden chamber migration assay. Migration abilities of
MCF12A cells expressing wild-type EZH2 (WT), EZH2S363A, EZH2T367A, or vector
control were determined using 24-well Boyden chamber plates with an 8 μm pore
size polycarbonate filter (BD Biosciences) as described. Numbers of migrated cells
were counted under a light microscopy and are shown as bar graph. Representative
images are shown at the top.
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3-5 H3K27 trimethylation is inversely correlated with GSK3 activity in breast
cancer patients
To examine the pathological relevance of EZH2 regulation by GSK3, we
analyzed correlation between the activity of GSK3 and the enzymatic activity of
EZH2 in human breast tumor specimens. Since GSK3-mediated phosphorylation
of EZH2 did not affect EZH2 expression level but reduce H3K27 trimethylation, and
it is known that Ser9 phosphorylation can inactivate GSK3 activity and the
measurement of Ser9 phosphorylation can be used to determine GSK3
inactivation (Ding, He et al. 2007), we compared expression of H3K27 trimethylation
with level of GSK3 phosphorylation at Ser9 in tumor tissue samples from 110
breast cancer patients. Consistently, immunohistochemical staining revealed that
the level of GSK3 phosphorylation at Ser9 was positively correlated with the
expression of H3K27 trimethylation (p = 0.006; Table 3-1 and Figure. 3-5). This
result suggested that GSK3 activity is inversely related to EZH2 activity in breast
cancer tissues.
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Figure 3-5. Trimethylation of H3K27 is positively correlated with the
expression of Ser9 GSK3 phosphorylation.

A. Representative cases of IHC staining for pS9-GSK3 expression and
H3K27 trimethylation. One hundred ten breast tumor tissue samples were
subjected

to

immunohistochemical

staining

with

antibodies

specific

to

phosphorylated GSK3 at Ser9 and H3K27 trimethylation, respectively. Case 1
shows a representative specimen with high expression of Ser9 phosphorylation of
GSK3 and H3K27 trimethylation. Case 2 is a sample with low expression of pSer9GSK3 and H3K27me3.
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Table 3-1.
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3-6 Summary
In this study, we identified an interesting regulatory mechanism by which
GSK3 regulates EZH2 activity via direct phosphorylation. Our findings
demonstrated that alteration of GSK3 activity inversely changed H3K27
trimethylation without alteration of EZH2 protein level. We confirmed that GSK3
physically interacts with and found that their interaction is mainly in the cytosol.
GSK3 phosphorylates EZH2 at Ser363 and Thr367 in vitro, and activation of
GSK3 increases Thr367 phosphorylation in vivo. Moreover, the GSK3
phosphorylation sites are evolutionarily conserved among various species.
Consistently, these modifications do not alter EZH2 protein expression nor affect
EZH2’s association with SUZ12 and EED, but suppresses H3K27 trimethylation.
Through functional assays, we found that nonphosphorylable mutant EZH2
enhanced cell migration and cell growth in an anchorage-independent manner,
indicating that GSK3’s regulation is critical for the oncogenic functions of EZH2.
Notably, the immunohistochemical staining results revealed that inactivation of
GSK3 is significantly correlated with higher level of H3K27 trimethylation in breast
cancer patients. Therefore, we proposed that GSK3 regulates tumorigenesis via
directly mediating EZH2 phosphorylation (Figure 3-6).
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Figure 3-6. Proposed model.

Figure 3-6. Proposed model of GSK3-mediated regulation of EZH2. GSK3
phosphorylates EZH2 at Ser363 and Thr367, which suppresses H3K27
trimethylation and EZH2 oncogenic functions.
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Chapter 4
Discussion
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Epigenetic regulation, including histone modification, is an essential
mechanism in control of cell differentiation and tissue development through
mediating gene expression without modifying DNA sequence. Alterations in this
regulation, such as aberrant expression or activation of epigenetic regulators,
undoubtedly change regular gene expression, which often induce neoplastic cell
transformation and tumor growth. EZH2, a histone methyltransferase, is a key
player in normal differentiation and development by catalyzing trimethylation of
H3K27, leading to epigenetically silencing of specific gene expression.
Overexpression or activation of EZH2 has been associated with several types of
cancers and is related to aggressive disease and poor outcome. Studies have also
demonstrated that EZH2 contributes to tumorigenesis through promoting malignant
transformation,

cell

proliferation,

invasion

and

migration.

The

histone

methyltransferase activity of EZH2 plays a critical role in these processes by
repressing specific gene expressions, such as RAD51, CDH1 (E-cadherin),
FOXC1, CDKN1C (p57KIP2), through trimethylation of H3K27 in these target gene
promoters. The results in the present study suggested that H3K27 trimethylation is
negatively regulated by GSK3 phosphorylation of EZH2. GSK3 phospho-mimic
mutant EZH2 reduces H3K27 trimethylation and vice versa. Consistently, this
observation was supported by our immunohistochemical staining analysis which
revealed that inactivation of GSK3 is significantly correlated with higher level of
H3K27 trimethylation in 110 breast cancer patients. GSK3 is frequently inactivated
and inactivation of GSK3 contributes to tumor development in certain types of
cancers. Our study provides a link between GSK3 and epigenetic regulator and a
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plausible explanation for the tumor promoting events controlled by EZH2H3K27me3 pathway. These findings that EZH2 is subjected to GSK3 regulation
are consistent with a recent study showing that GSK3 negatively regulates EZH2
expression in nasopharyngeal cancer cells and that the level of GSK3
phosphorylation at Ser9 is associated with higher EZH2 protein expression in
patients with nasopharyngeal carcinoma (Ma, Wei et al. 2013).
GSK3 is known to be involved in tumor development, but its role in
tumorigenesis remains controversial: in some types of cancer like pancreatic
cancer, it contributes to tumorigenesis; in others such as breast cancer, it functions
as a tumor suppressor (Luo 2009). In our study, we demonstrated that GSK3
nonphosphorylable mutant EZH2 (EZH22A, EZH2S363A, EZH2T367A) enhances cell
migration and cell growth in breast cancer and mammary epithelial cells. Together
with previously published reports, our results further strengthened the role of
GSK3 as a tumor suppressor in breast cancer and implied that inactivation of
GSK3 is one of the mechanisms enhancing EZH2 activity in cancer.
In many substrates, GSK3 interaction is associated with the switch of their
subcellular localization. A well-known example is -catenin. GSK3 physically
interacts with and phosphorylates -catenin in the cytosol, which leads to-catenin
inactivation. Once GSK3 is inactivated, -catenin translocates into nucleus and
activates its target genes. In this study, we found that GSK3 mainly interacts with
EZH2 in the cytosol and GSK3 phosphorylation does not result in EZH2
degradation. EZH2 has been shown to regulate cell migration through interaction
with a cytosolic and cytoskeletal protein, talin, suggesting that EZH2 has a cytosolic
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function. Our finding implies that cytosolic interaction between GSK3 and EZH2
may lead to inhibition of EZH2 activity in the nucleus. Their cytosolic interaction
does not affect EZH2 protein level, making it possible that this interaction may
enhance EZH2 cytosolic function. Further investigation is needed to clarify the role
of their interaction in the cytosol.
Studies have shown that EZH2 can be translationally modified by
phosphorylation. Previous phosphoproteomic analyses of EZH2 have identified
many phosphorylation residues in mouse tissues and human cell lines, including
Ser362, Ser363, Ser366 and Thr367 (Mayya, Lundgren et al. 2009, Huttlin,
Jedrychowski et al. 2010). Our work confirmed that GSK3 phosphorylates EZH2
at Ser363 and Thr367. As mentioned earlier, GSK3 has a preference for its
substrates by recognizing a phosphorylation motif. Interestingly, the identified
phosphorylation sites on EZH2 are compatible with this consensus motif.
Furthermore, these two phosphorylation sites are highly conserved residues,
implying that this regulation could be functional in other organisms. NIH-3T3 cells
expressing phospho-mimic mutant EZH2 have lower H3K27 trimethylation,
supporting this notion. Previously, a study revealed that EZH2 can be
phosphorylated at Thr367 by p38in muscle stem cells (Palacios, Mozzetta et al.
2010). p38-mediated EZH2 phosphorylation leads to Pax7 repression through
trimethylation of H3K27 in its promoter while inhibition of p38-EZH2 pathway
promotes muscle stem cell proliferation. In our study, we observed that GSK3
nonphosphorylable mutant, EZH2T367A, increased global H3K27 trimethylation in
mammary epithelial cells and enhanced cell growth and migration. Activation of
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GSK3 upregulated Thr367 phosphorylation in vivo. Our findings and previous
report suggested that the biological significance of EZH2 phosphorylation at Thr367
is cell context-dependent.
Unlike other kinases, GSK3 prefers a pre-phosphorylated substrate for
priming phosphorylation. In this modification, GSK3 phosphorylates a substrate at
target serine/threonine residue after this substrate has been pre-phosphorylated at
another serine/threonine 4 amino acids C-terminal to the target site by other kinase.
Apart from priming phosphorylation, GSK3 can phosphorylate its substrate at
more than one sites. For example, SNAIL contains several consecutive
phosphorylation motifs and GSK3 phosphorylates SNAIL at 6 serines in a
sequential manner starting from the residue closest to C-terminus (Zhou, Deng et
al. 2004). Our in vitro kinase assay revealed that GSK3 phosphorylates EZH2
without primed phosphorylation. Moreover, Thr367A mutant totally abolished
GSK3 phosphorylation but Ser363 did not. This promoted us to speculate the
possibility of sequential phosphorylation. Although a subsequent in vitro kinase
assay did not prove it, the possibility cannot be excluded.
EZH2 is a histone methyltransferase and its enzymatic activity requires the
association with SUZ12 and EED. Methylation of H3K27 is catalyzed by
EZH2/PRC2 complex in a progressive manner, in which EZH2/PRC2 exerts its
action on its substrates, histone H3, H3K27me1, H3K27me2, to converts them into
H3K27me1, H3K27me2 and H3K27me3 by addition of one methyl group,
respectively. In the present study, an in vitro methylation assay using recombinant
histone H3 protein as substrate revealed that monomethylation of H3K27 catalyzed
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by phospho-mimic mutant EZH2 was reduced but dimethylation (data not shown)
or trimethylation of H3K27 was not. As the substrate used in this assay was
recombinant histone H3 protein which has no modification on H3K27 and the
methylation of H3K27 catalyzed by EZH2 is a successive process from mono-, dito trimethylation, the result suggested that phospho-mimic mutant EZH2 exhibits
lower histone methyltransferase activity than that of wild-type EZH2. In this
experiment, the signals of dimethylation and trimethylation of H3K27 were similar
in wild-type and mutant EZH2 but were not detectable in control vector, I reasoned
that they might be background signals occurring due to immunoprecipitation of
Flag-EZH2.
The histone methyltransferase activity of EZH2 can be regulated by sitespecific

phosphorylations

in

different

mechanisms.

For

example,

JAK2

phosphorylates EZH2 at Tyr641, which is located on the catalytic SET domain,
promotes EZH2’s interaction with -TrCP and leads to its degradation
(Sahasrabuddhe, Chen et al. 2015). Thr487 phosphorylation by CDK1 disrupts
PRC2 assembly and reduces H3K27 trimethylation (Wei, Chen et al. 2011). In the
current study, these two phosphorylation sites we identified are neither located on
the SET domain nor in the regions of SUZ12 or EED binding. Compatible with the
observation, we and others (Palacios, Mozzetta et al. 2010) did not find that
mutations at these sites (EZH22A, EZH2S363A, EZH2T367A) change the association of
EZH2 with EED or SUZ12. Furthermore, we did not detect alteration in EZH2
protein expression upon this regulation. However, our work revealed that GSK3
interacts with EZH2 and, unexpectedly, their interaction is mainly in the cytosol. As
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mentioned previously, EZH2 is able to interact with cytosolic protein (Gunawan,
Venkatesan et al. 2015). Thus, we hypothesized that GSK3 regulates H3K27
trimethylation by mediating EZH2’s localization (Figure 4-1). Further investigation
is needed to verify this hypothesis. In addition to the possibility of switch in EZH2’s
subcellular localization, GSK3 phosphorylation may suppress the enzymatic
activity of EZH2 via modulating its interaction with other factors. EZH2 and PRC2
complex has been shown to interact with noncoding RNA (ncRNA) and this
interaction regulates their function. One well-known example is X-chromosome
inactivation, which is an important developmental process in mammals. X
inactivation induces the expression of an ncRNA, X-inactive specific transcript
(XIST), which helps to recruit EZH2/PRC2 complex to trimethylate H3K27 on
inactivated X-chromosome (Margueron and Reinberg 2011). Similarly, another
ncRNA, HOTAIR, has been demonstrated to be able to interact with EZH2. Notably,
phosphorylation of EZH2 at Thr345 promotes its binding to HOTAIR and an ncRNAbinding domain between residues 342 and 370 has been identified (Kaneko, Li et
al. 2010). Interestingly, GSK3 phosphorylation sites on EZH2, Ser363 and Thr367,
is located on this domain. Whether GSK3 phosphorylation mediates EZH2
interaction with ncRNA and consequently suppresses H3K27 trimethylation needs
further studies (Figure 4-2).
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Figure 4-1. Cytosolic interaction of GSK3 and EZH2 may lead to
inactivation of EZH2’s enzymatic activity

4-1. Hypothesis: GSK3 may trap EZH2 in the cytosol. The majority of EZH2
proteins and functions are in the nucleus. A recent study reported that EZH2 can
interact with cytosolic protein and has cytosolic function. Once GSK3 binds to
EZH2, EZH2 may stay in the cytosol, thereby leading to reduce its HMT activity and
H3K27me3 level.
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Figure 4-2. GSK3 phosphorylation may affect EZH2 interaction with ncRNA

A. The ncRNA binding region of EZH2. EZH2 can interact with ncRNA and its
binding domain has been identified between residues 342 and 370. GSK3
phosphorylation sites, Ser363 and Thr367, are located within this region.

B. Hypothesis: GSK3 phosphorylation may regulate EZH2 association with
ncRNA to suppress H3K27 trimethylation.
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PRC2 complex is essential in regulating self-renewal capacity in embryonic
and adult stem cells and EZH2 has been reported to promote expansion of tumor
initiating cell population. At the beginning of this study, we aimed to study the role
of GSK3-mediated EZH2 regulation in cancer stem cells. However, we did not
observe differences between wild-type and GSK3 nonphosphorylable mutant
EZH2 stable cells using flow cytometry analysis and mammosphere formation
assay. Interestingly, we found that GSK3 nonphosphorylable mutants enhance
cell growth in an anchorage-independent manner but not affect cell proliferation in
2D culture. Furthermore, these mutants increase cell migration ability. EZH2 has
been shown to promote colony formation and cell migration. Our observation is
compatible with previous studies and GSK3 inactivation augments these EZH2’s
oncogenic functions. EZH2 has also been demonstrated to regulate cell growth and
migration through repressing tumor suppressor expression by catalyzing
trimethylation of H3K27. It is possible that GSK3 mediates these EZH2’s
oncogenic functions through modulating these target gene repression via H3K27
trimethylation. On the other hand, GSK3 is a multi-tasking kinase involved in many
signaling pathways, such as AKT, ERK and WNT/-catenin pathway. The
regulation of EZH2 by GSK3 suggests that these oncogenic pathways could
control cell growth and migration by mediating GSK3 activity. Recently, an
interesting study reported that specific KRAS mutation regulates EZH2 protein
expression through the PI3K/AKT and/or MEK/ERK signaling pathways in lung
cancer (Riquelme, Behrens et al. 2016). EZH2 inhibition enhances the sensitivity to
MEK-ERK or PI3K/AKT targeted therapies in specific KRAS-mutant lung cancer
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cells and tumors. Since GSK3 is known to be inactivated by AKT or ERK, our work
suggests a direct role of the GSK3-EZH2 pathway in this scenario and offers a
rationale for enhancing GSK3 activity and/or targeting EZH2 in anti-cancer
therapy.
Since GSK3 is widely involved in several cellular processes, its deregulation
has been found in many diseases, such as neuropsychiatric disorder, or diabetes
mellitus. Inhibitors targeting GSK3 has been developed and used to treat these
diseases. As mentioned earlier, GSK3 has tumor promoting effect in certain types
of cancer. GSK3 inhibitors have also been tested in the anticancer treatment,
particularly in treating hematological malignancy. However, inactivation of GSK3
by these inhibitors may cause a concern for tumor development like breast cancer
as GSK3 inhibition can activate EZH2-H3K27me3 pathway and enhance its
oncogenic functions.
Because of EZH2’s importance in tumorigenesis, several inhibitors targeting
EZH2 have been developed and tested in preclinical and clinical trials. These
inhibitors are summarized in Table 4-1 (Kim and Roberts 2016). Most of them are
studied in non-Hodgkin lymphoma, few are in solid tumors. All of these compounds
inhibit EZH2’s enzymatic activity. Because GSK3 attenuates EZH2’s enzymatic
activity, inactivation of GSK3 may be a biomarker for EZH2 targeting therapy.
Moreover, therapies enhancing GSK3 activity in combination with EZH2 inhibitor
may be a novel therapeutic strategy in anti-cancer management.
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Table 4-1. EZH2 inhibitors in development
Table 4-1. EZH2 inhibitors in development
Compound

Mechanism

Cancer type

DZNep

SAH hydrolase inhibitor

Pre-clinical

EI1

SAM-competitive inhibitor

Pre-clinical

EPZ005687

SAM-competitive inhibitor

Pre-clinical

GSK343

SAM-competitive inhibitor

Pre-clinical

UNC1999

SAM-competitive inhibitor

Pre-clinical

SAH-EZH2

Disrupt the protein interaction
between EZH2 and EED

Pre-clinical

GSK126

SAM-competitive inhibitor

Non-Hodgin lymphoma

Phase I

CPI-1205

SAM-competitive inhibitor

Non-Hodgin lymphoma

Phase I

EPZ-6438

SAM-competitive inhibitor

Non-Hodgin lymphoma;
Soft tissue sarcoma

Phase I/II
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Trial status

Conclusion:
The results in this study indicates that GSK3 negatively regulates EZH2
activity through phosphorylation. We confirmed that GSK3 physically associates
with EZH2 and their interaction is mainly in the cytosol. We found that GSK3
phosphorylates EZH2 at Ser363 and Thr367 and activation of GSK3 enhances
T367 phosphorylatioin in vivo. Cells expressing mutant EZH2 to block
phosphorylation by GSK3 have higher H3K27 trimethylation and enhanced ability
of cell migration and anchorage-independent growth, which suggests that
inactivation of GSK3 augments EZH2’s oncogenic functions. Furthermore, our
results indicate that inactivation of GSK3 measured by GSK3 phosphorylation at
Ser9 may lead to higher EZH2 activity characterized by excessive expression of
H3K27 trimethylation in human breast cancer tissues, suggesting the clinical
significance of this regulation in tumorigenesis. Taken together, our study
contributes to a better understanding of tumor progression and will be helpful to
develop therapeutic strategies for future anti-cancer management.
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Chapter 5
Future Work and Direction

104

This study leaves several questions: First, it is important to investigate what
target genes of EZH2 and H3K27me3 are affected by GSK3 regulation. As
mentioned earlier, EZH2 can regulate cell proliferation, growth and migration
through repression of several target genes by catalyzing H3K27 trimethylation,
such

as

RAD51,

CDH1

(E-cadherin),

FOXC1

and

RKIP.

Chromatin

immunoprecipitation (ChIP) can be performed to examine the binding of EZH2
and/or H3K27me3 to these gene promoters in cells expressing wild-type,
nonphosphorylable or phospho-mimic mutant EZH2 or in cells with or without
activation of GSK3or both. The mRNA expression of these genes can also be
measured by qRT-PCR in these cells. However, EZH2 binding to these genes and
their expression may not be affected by GSK3 regulation. ChIP sequencing can
be utilized to identify potential target genes which will be important in GSK3mediated EZH2’s oncogenic functions.
Second, what is the role of cytosolic interaction between GSK3 and EZH2
is not clear. As described in discussion, their cytosolic interaction may “trap” EZH2
in the cytosol, leading to a reduction of nuclear EZH2 amount, thereby
downregulating H3K27 trimethylation. To verify this hypothesis, nuclear and
cytosolic fraction of EZH2 protein amount can be examined in cells with or without
activation of GSK3. To explore whether GSK3 phosphorylation of EZH2 switches
its subcellular localization, nuclear and cytosolic EZH2 can be analyzed in cells
transfected with wild-type, nonphosphorylable or phospho-mimic mutant EZH2.
Because their cytosolic interaction does not affect EZH2 protein level, it might be
possible that this interaction enhance EZH2 cytosolic function. Whether EZH2 gains
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its cytosolic function by GSK3b phosphorylation is worthwhile to be further
investigated.
Moreover, GSK3 phosphorylation sites locate on the ncRNA binding region
of EZH2. Actually, EZH2 is an RNA binding protein. A sucrose gradient experiment
can be performed for preliminary understanding whether GSK3 phosphorylation
affects EZH2 association with RNA using wild-type and mutant EZH2 stable cells
with or without RNase treatment. EZH2 is known to interact with several ncRNAs,
such as Rep A, HOTAIR and Metastasis Associated Lung Adenocarcinoma
Transcript 1 (MALAT-1). An RNA immunoprecipitation (RIP) can be utilized to
specifically analyze the affinity of wild-type and mutant EZH2 to these ncRNAs. The
ncRNAs interacting with EZH2 can be knocked down to determine if their interaction
modulate H3K27 trimethylation.
In addition to these plans, I would like to test this regulation in lung cancer.
Lung cancer is still the leading cause of cancer-related death in the United States
and worldwide in spite of advances in anti-cancer treatment. Non-small cell lung
cancer (NSCLC) accounts for about 85% of all cases. In patients with NSCLC,
higher expression of EZH2 is a poor prognostic marker and associated with a
metastatic disease (Behrens, Solis et al. 2013, Wang, Zhao et al. 2016). Studies
has also demonstrated that overexpression of EZH2 contributes to cancer cell
migration and tumorigenesis and EZH2 knockdown reduces cell proliferation and
growth in NSCLC (Cao, Ribeiro Rde et al. 2012, Xu, Hou et al. 2013, Kim, Kim et
al. 2015, Serresi, Gargiulo et al. 2016), part of these studies have shown that EZH2
regulation is through catalyzing trimethylation of H3K27. Recently, a study reported
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that EZH2 inhibitor, GSK126, sensitizes NSCLC cell lines with BRG1 or EGFR
mutation to topoisomerase II inhibitor Etoposide treatment (Fillmore, Xu et al. 2015).
These evidence suggests that EZH2 play an important role in NSCLC
tumorigenesis and EZH2 could be a therapeutic target in selective patients with
NSCLC. On the other hand, GSK3 expression and activity are relatively low in
NSCLC, in contrast to its counterpart, small cell lung cancer (SCLC) (Zheng, Saito
et al. 2007, Byers, Wang et al. 2012). A significant portion of NSCLC patients
harbors KRAS or EGFR mutation, both can lead to inactivation of GSK3. Thus,
the regulation identified in this study potentially provides a therapeutic strategy that
GSK3 inactivation may be a useful marker to guide anti-EZH2 treatment in NSCLC
patients if this signaling pathway exists in NSCLC. To examine whether this
regulation occurs in NSCLC cell lines, we used the same approach to alter GSK3
activity by treating cells with lithium chloride and staurosporine. The preliminary
result reveals that, similar with previous findings in breast cancer and mammary
epithelial cell lines, lithium chloride treatment increases H3K27 trimethylation and,
more significantly, staurosporine reduces its level in KRAS-mutant A549 and
EGFR-mutant HCC827 NSCLC cell lines (Figure 5-1), implying that this regulation
may exist in NSCLC. An immunohistochemical staining analysis can be used to
further evaluate the clinical relevance and significance of this regulation in NSCLC
cancer patients. To investigate whether inactivation of GSK3 can be utilized to
guide EZH2 targeting therapy in NSCLC, the sensitivity (IC50) of NSCLC cell lines
to EZH2 inhibitors can be measured to correlate with GSK3 activity determined by
the level of GSK3 phosphorylation at Ser9. Furthermore, increasing GSK3
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activity in cells with relatively inactivated GSK3 status by expressing constitutively
active

GSK3

can

be

performed

to

determine

whether

activation

of

GSK3enhances efficacy of EZH2 inhibitor. Alternatively, GSK3 activity can be
enhanced by chemotherapeutic drugs or EGFR-TKI. A combination therapy with
EZH2 inhibitor plus a drug enhancing GSK3 activity can be tested according to
this regulation.
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Figure 5-1. GSK3 negatively regulates H3K27 trimethylation in NSCLC cell
lines.

5-1. Alteration of GSK3 activity changes H3K27 trimethylation in NSCLC cell
lines. NSCLC cell lines, A549 and HCC827 cells were treated with lithium chloride
(LiCl), staurosporine as indicated. Cell lysates were subjected to western blot
analysis with the indicated antibodies.
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